documents incorporated reference written oral statements company makes time time contain certain forwardlooking statements within meaning section securities act section e securities exchange act identify forwardlooking statements fact use words expect anticipate estimate target may project guidance intend plan believe words terms similar meaning expression connection discussion future operating financial performance one also identify forwardlooking statements fact relate strictly historical current facts forwardlooking statements based current expectations involve inherent risks uncertainties table contents including factors could delay divert change could cause actual outcomes differ materially current expectations statements likely relate among things companys goals plans projections regarding financial position results operations cash flows market position product development product approvals sales efforts expenses performance results current anticipated products outcome contingencies legal proceedings financial results based current expectations involve inherent risks uncertainties including internal external factors could delay divert change next several years although possible predict identify factors may include limited following new government laws regulations health care reform initiatives united states state federal level countries ii changes fda foreign regulatory approval processes may cause delays approving preventing approval new products iii tax changes phasing tax benefits heretofore available united states certain foreign countries iv new laws regulations judicial decisions affecting pricing marketing within across jurisdictions v changes intellectual property law competitive factors new products developed competitors lower prices superior performance features otherwise competitive companys current products ii generic competition companys products mature patents expire products iii technological advances patents attained competitors iv problems licensors suppliers distributors v business combinations among companys competitors major customers difficulties delays inherent product development manufacturing sale products may appear promising development fail reach market approved additional indications number reasons including efficacy safety concerns inability obtain necessary regulatory approvals difficulty excessive cost manufacture ii failure products achieve maintain commercial viability iii seizure recalls pharmaceutical products forced closings manufacturing plants iv failure obtain imposition limitations use loss patent intellectual property rights v failure company vendors suppliers comply current good manufacturing practices application regulations quality assurance guidelines could lead temporary manufacturing shutdowns product shortages delays product manufacturing vi manufacturing distribution problems including changes manufacturing production sites manufacturing capacity due regulatory requirements changes types products produced biologics physical limitations could impact continuous supply legal difficulties including lawsuits claims proceedings investigations preclude delay commercialization products adversely affect operations profitability liquidity financial condition including intellectual property disputes ii adverse decisions litigation including product liability commercial cases iii inability obtain adequate insurance respect type liability iv recalls pharmaceutical products forced closings manufacturing plants v failure fulfill obligations supply contracts government customers may result liability vi government investigations including relating wholesaler inventory financial restatement product pricing promotion vii claims asserting violations securities antitrust federal state pricing laws viii environmental health safety matters ix tax liabilities assurance increase scope matters future lawsuits claims proceedings investigations material increasing pricing pressures worldwide including rules practices managed care groups institutional governmental purchasers judicial decisions governmental laws regulations related medicare medicaid healthcare reform potential impact importation legislative otherwise pharmaceutical reimbursement pricing general fluctuations buying patterns inventory levels major distributors retail chains trade buyers may result seasonality pricing wholesaler buying decisions including effect incentives offered companys wholesaler inventory management policies including workdown changes wholesaler inventory levels factors greater expected costs difficulties including unanticipated effects difficulties acquisitions dispositions events including obtaining regulatory approvals connection evolving business strategies legal defense costs insurance expense settlement costs risk adverse decision related litigation changes advertising promotional spending categories spending may affect sales changes product mix may affect margins table contents changes companys structure operations revenues costs staffing efficiency resulting acquisitions divestitures mergers alliances restructurings strategic initiatives economic factors company control changes business economic conditions including limited changes interest rates fluctuation foreign currency exchange rates changes business political economic conditions due political social instability military armed conflict nationalization assets debt payment moratoriums restrictions commerce actual threatened terrorist attacks united states parts world related military action changes accounting standards promulgated fasb sec aicpa may require adjustments financial statements capacity efficiency reliability security potential breakdown invasion destruction interruption information systems reliance company vendors partners third parties meet contractual regulatory obligations relation arrangements company results clinical studies relating companys competitors products although company believes prudent plans assumptions assurance given goal plan set forth forwardlooking statements achieved readers cautioned place undue reliance statements speak date made company undertakes obligation release publicly revisions forwardlooking statements result new information future events otherwise table contents item quantitative qualitative disclosures market risk company exposed market risk due changes currency exchange rates interest rates reduce risk company enters certain derivative financial instruments available costeffective basis hedge underlying economic exposure instruments managed consolidated basis efficiently net exposures thus take advantage natural offsets derivative financial instruments used speculative purposes gains losses hedging transactions offset gains losses underlying exposures hedged ineffective portion hedges reported earnings occurs foreign exchange option contracts forward contracts used hedge anticipated transactions companys primary foreign currency exposures relation us dollar euro japanese yen canadian dollar mexican peso table summarizes companys outstanding foreign exchange contracts december fair value foreign exchange contracts based yearend currency rates blackscholes model case option contracts fair value option contracts forward contracts viewed relation fair value underlying hedged transactions overall reduction exposure adverse fluctuations foreign currency exchange rates weighted average notional fair strike price amount value maturity dollars millions except currency rates foreign exchange forwards australian dollar british pound canadian dollar euro polish zloty swedish krona swiss franc others option contracts japanese yen total contracts december company held option forward exchange contracts maturity dates notional amounts fair values maturity dates expressed table notional amount fair value year maturity millions millions december company held option contracts aggregate notional amount fair value million million respectively options give company right buy japanese yen specified rates company also held forward contracts aggregate notional amount million fair value forward contracts million recorded current liability contracts primarily related exposures euro canadian dollar australian dollar company obligated settle forward contracts based specified contract rates december balance deferred net aftertax losses option forward contracts included accumulated comprehensive income million million estimated reclassified earnings within next months year ended december impact hedge ineffectiveness earnings loss million additionally company uses forward contracts offset exposure certain currency assets liabilities forward contracts designated hedges therefore changes fair value derivatives recognized earnings occur december company recorded loss million related forward exchange contracts qualify hedge accounting treatment december company held option forward exchange contracts aggregate notional amount fair value million million respectively contracts primarily related exposures euro japanese yen canadian dollar australian dollar table contents addition foreign exchange hedge contracts noted company also uses foreign exchange forward contracts hedge foreign currency denominated monetary assets liabilities primary objective foreign exchange forward contracts protect us dollar value foreign currency denominated monetary assets liabilities effects volatility foreign exchange might occur prior receipt settlement us dollars foreign currency denominated monetary assets liabilities primarily denominated japanese yen euro forward contracts designated hedges marked market incomeexpense notional fair value amount foreign exchange forward contracts december million million respectively company uses derivative instruments part interest rate risk management policy derivative instruments used include interest rate swaps subject fairvalue hedge accounting treatment company executed several fixed floating interest rate swaps convert billion companys fixed rate debt paid variable rate debt year ended december company recognized net reduction interest expense million reflects benefit lower floating rate obtained swap agreement sfas requires revaluation fair value swap contracts well underlying debt hedged swap contracts underlying debt revalued resulting increase noncurrent assets million shortterm liabilities million longterm debt million increase noncurrent assets longterm debt million december respectively swap contracts generally held maturity used speculative purposes following table summarizes interest rate swaps outstanding december notional amount underlying variable rate interest rate contracts debt received maturity fair value dollars millions swaps associated month us notes due libor swaps associated month us notes due libor swaps associated month us notes due libor swaps associated month us notes due libor swaps associated month us notes due libor swaps associated month us notes due libor december company held interest rate swap contracts notional value million fair value million estimated change interest rate structure would material impact companys consolidated financial position results operations cash flows company million million longterm debt outstanding december respectively see item financial statementsnote shortterm borrowings longterm debt note financial instruments additional information company maintains cash cash equivalents marketable securities various financial institutions order limit exposure one financial institution financial institutions headquartered primarily north america europe table contents bristolmyers squibb company consolidated statement earnings millions except per share data item financial statements supplementary data year ended december earnings net sales cost products sold marketing selling administrative advertising product promotion research development acquired inprocess research development provision restructuring items net litigation charges net gain sales businessesproduct lines asset impairment charge investment imclone equity net income affiliates expense net total expenses earnings continuing operations minority interest income taxes provision income taxes minority interest net taxes earnings continuing operations discontinued operations net earnings net gain disposal net earnings earnings per common share basic earnings continuing operations discontinued operations net earnings net gain disposal net earnings diluted earnings continuing operations discontinued operations net earnings net gain disposal net earnings average common shares outstanding basic diluted dividends declared per common share accompanying notes integral part financial statements table contents bristolmyers squibb company consolidated statement comprehensive income retained earnings dollars millions comprehensive income net earnings comprehensive income foreign currency translation net tax benefit deferred losses derivatives qualifying hedges net tax liability tax benefit minimum pension liability adjustment net tax benefit available sale securities net tax liability total comprehensive income comprehensive income retained earnings retained earnings january net earnings cash dividends declared zimmer common stock dividend retained earnings december accompanying notes integral part financial statements table contents bristolmyers squibb company consolidated balance sheet dollars millions december assets current assets cash cash equivalents marketable securities receivables net allowances inventories including consignment inventory deferred income taxes net valuation allowances prepaid expenses total current assets property plant equipment net goodwill intangible assets net deferred income taxes net valuation allowances assets total assets liabilities current liabilities shortterm borrowings accounts payable accrued expenses accrued rebates returns us foreign income taxes payable dividends payable accrued litigation liabilities deferred revenue consigned inventory total current liabilities liabilities longterm debt total liabilities commitments contingencies stockholders equity preferred stock convertible series authorized million shares issued outstanding liquidation value per share common stock par value per share authorized billion shares million issued million issued capital excess par value stock restricted stock accumulated comprehensive loss retained earnings less cost treasury stock million common shares million total stockholders equity total liabilities stockholders equity accompanying notes integral part financial statements table contents bristolmyers squibb company consolidated statement cash flows dollars millions year ended december cash flows operating activities net earnings adjustments reconcile net earnings net cash provided operating activities depreciation amortization deferred income tax benefitexpense litigation settlement expense provision restructuring items gain sales businessesproduct lines including discontinued operations acquired inprocess research development loss gain disposal property plant equipment investment companies undistributed earningslosses affiliates net unfunded pension expense impairment charges asset writeoffs changes operating assets liabilities receivables inventories prepaid expenses assets deferred revenue consigned inventory litigation settlement payments accounts payable accrued expenses product liability us foreign income taxes payable liabilities net cash provided operating activities cash flows investing activities purchases net sales maturities marketable securities additions property plant equipment capitalized software proceeds disposal property plant equipment investment companies proceeds sales businessesproduct lines imclone milestone payment purchase acordis specialty fibres purchases trademarks patents licenses businesses investments companies divestiture acquisition costs net cash used investing activities cash flows financing activities shortterm borrowings net repayments longterm debt borrowings longterm debt repayments issuances common stock stock plans purchases treasury stock dividends paid net cash used financing activities effect exchange rates cash increase decrease cash cash equivalents cash cash equivalents beginning year cash cash equivalents end year accompanying notes integral part financial statements table contents bristolmyers squibb company notes consolidated financial statements note accounting policies basis consolidation consolidated financial statements include accounts bristolmyers squibb company bms company bristolmyers squibb controlled majority owned subsidiaries intercompany balances transactions eliminated certain prior year amounts reclassified conform current year presentation use estimates preparation financial statements conformity us generally accepted accounting principles gaap requires use estimates assumptions affect reported amounts assets liabilities disclosure contingent assets contingent liabilities date financial statements reported amounts revenues expenses reporting period significant assumptions employed estimates used determining values intangible assets restructuring charges accruals sales rebate return accruals legal contingencies tax assets tax liabilities well estimates used applying revenue recognition policy accounting retirement postretirement benefits including actuarial assumptions actual results could differ estimated results revenue recognition company recognizes revenue substantially risks rewards ownership transferred customer case certain sales made nutritionals healthcare segments certain nonus businesses within pharmaceuticals segment revenue recognized date receipt purchaser revenues reduced time sale reflect expected returns estimated based historical experience additionally provisions made time sale discounts rebates estimated sales allowances based historical experience updated changes facts circumstances appropriate provisions recorded reduction revenue case sales made wholesalers result incentives excess wholesalers ordinary course business inventory level time understanding agreement course dealing consistent business practice company would extend incentives based levels excess inventory connection future purchases time incentives would cover substantially vary directly wholesalers cost carrying inventory excess wholesalers ordinary course business inventory level substantially risks rewards ownership transfer upon shipment accordingly sales accounted using consignment model determination sales wholesaler meet foregoing criteria involves evaluation variety factors number complex judgments consignment model company recognize revenue upon shipment product rather upon shipment product company invoices wholesaler records deferred revenue gross invoice sales price classifies inventory held wholesalers consignment inventory companys cost inventory company recognizes revenue consignment inventory longer subject incentive arrangements later inventory sold wholesalers customers firstin firstout fifo basis sales rebate return accruals medicaid rebate accruals million million december respectively women infants children wic rebate accruals million million respectively managed healthcare rebate contractual discount accruals million million december respectively rebate accruals established period related revenue recognized resulting reduction sales establishment liability included accrued liabilities accrual recorded based estimate proportion recorded revenue result rebate return prime vendor chargeback accruals established similar manner recorded reduction accounts receivable million million december respectively income taxes provision income taxes determined using asset liability approach accounting income taxes approach deferred taxes represent future tax consequences expected occur reported amounts assets liabilities recovered paid provision income taxes represents income taxes paid payable current year plus change deferred taxes year deferred taxes result differences financial tax bases companys assets liabilities adjusted changes tax rates tax laws changes enacted valuation allowances recorded reduce deferred tax assets likely tax benefit realized december company approximately billion undistributed earnings foreign subsidiaries company accrued provision million estimated deferred taxes fourth quarter anticipation repatriating approximately billion earnings pursuant american jobs creation act ajca taxes table contents bristolmyers squibb company notes consolidated financial statements continued note accounting policies continued provided balance undistributed earnings approximately billion company invested expects invest undistributed earnings permanently offshore future earnings repatriated united states company determines earnings remitted foreseeable future additional tax provisions would required due complexities tax laws assumptions would made practicable estimate amounts income taxes would provided ajca provides temporary percent dividends received deduction certain cash distributions earnings foreign subsidiaries deduction would result federal tax rate approximately repatriated earnings assuming marginal federal tax rate earnings qualify deduction repatriated earnings must reinvested united states pursuant domestic reinvestment plan approved companys chief executive officer board directors january department treasury issued guidelines permitted investments plan company expects meet requirements criteria qualify deduction however several provisions ajca require clarification may addressed coming months treasury congress companys estimate tax cost related repatriation december based tax laws effect extent tax laws guidance changes estimate revised companys estimate may also revised result changes companys factual assumptions may occur guidance financial accounting standards board fasb staff position fsp application fasb statement accounting income taxes tax deduction qualified production activities provided american jobs creation act deduction treated special deduction described statement financial accounting standards sfas special deduction affect deferred tax assets liabilities existing enactment date rather impact deduction reported period deduction claimed companys tax return company establishes liabilities possible assessments tax authorities resulting known tax exposures amounts represent reasonable provision taxes ultimately expected paid may need adjusted time information becomes known cash cash equivalents cash equivalents primarily highly liquid investments original maturities three months less time purchase recorded cost approximates fair value marketable securities company accounts marketable securities accordance sfas accounting certain investments debt equity securities company determined appropriate classification marketable securities availableforsale time purchase december companys investments marketable securities reported fair value unrealized gains losses reported component accumulated comprehensive income loss stockholders equity amortized cost debt securities adjusted amortization premiums accretion discounts date purchase maturity amortization included interest income addition deduction coupon interest earned investments company follows investment managers method determining cost basis computing realized gains losses sale available forsale securities average cost method realized gains losses included income expense inventory valuation inventories generally stated average cost excess market capital assets depreciation expenditures additions renewals improvements capitalized cost depreciation generally computed straightline method based estimated useful lives related assets estimated useful lives major classes depreciable assets years buildings years machinery equipment fixtures company periodically evaluates whether current events circumstances indicate carrying value depreciable assets may recoverable table contents bristolmyers squibb company notes consolidated financial statements continued note accounting policies continued impairment longlived assets effective january company adopted provisions sfas accounting impairment longlived assets adoption sfas material effect consolidated financial statements company sfas establishes accounting impairment longlived tangible intangible assets goodwill disposal segment business pursuant sfas company periodically evaluates whether current facts circumstances indicate carrying value depreciable assets held used may recoverable circumstances determined exist estimate undiscounted future cash flows produced longlived asset appropriate grouping assets compared carrying value determine whether impairment exists asset determined impaired loss measured based difference assets fair value carrying value estimate assets fair value based quoted market prices active markets available quoted market prices available estimate fair value based various valuation techniques including discounted value estimated future cash flows company reports asset disposed lower carrying value estimated net realizable value capitalized software certain costs obtain internal use software significant systems projects capitalized amortized estimated useful life software ranges three ten years costs obtain software projects significant expensed incurred capitalized software net accumulated amortization included assets million million december respectively amortization expense million million million years ended december respectively investments january company adopted fasb interpretation fin interpretation consolidation variable interest entities interpretation arb fin clarifies application accounting research bulletin arb consolidated financial statements certain entities equity investors characteristics controlling financial interest sufficient equity risk entity finance activities without additional subordinated financial support parties entities known variable interest entities vies fasb issued revision fin fin r december fin r effective interim period ending march new existing vies adoption fin effect companys financial statements entity meet definition vie fin company accounts entity provisions accounting research bulletin arb consolidated financial statements amended sfas consolidation majorityowned subsidiaries requires company consolidates majority owned subsidiaries ability exercise control company accounts less owned companies ability exercise significant influence using equity method accounting companys share net income losses equity investments included equity net income affiliates consolidated statement earnings company periodically reviews equity investments impairment adjusts investments fair value decline market value deemed temporary company recorded asset impairment charge million otherthantemporary decline market value imclone systems incorporated imclone longterm investments securities comprise marketable equity securities securities investments market values readily available included assets marketable equity securities classified availableforsale reported fair value fair value based quoted market prices end reporting period securities investments market values readily available carried cost unrealized gains losses reported net related tax effects component accumulated comprehensive income loss stockholders equity sold time sale gains losses calculated specific identification method recognized incomeexpense losses also recognized income decline market value deemed temporary goodwill intangible assets company adopted sfas goodwill intangible assets january certain provisions adopted july respect amortization goodwill arising acquisitions made june sfas addresses initial recognition measurement intangible assets acquired outside business combination recognition measurement goodwill intangible assets subsequent acquisition sfas goodwill longer amortized subject annual impairment tests table contents bristolmyers squibb company notes consolidated financial statements continued note accounting policies continued accordance sfas goodwill tested impairment upon adoption new standard annually thereafter sfas requires goodwill tested impairment using twostep process first step identify potential impairment second step measures amount impairment loss goodwill deemed impaired carrying amount reporting units goodwill exceeds estimated fair value company completed goodwill impairment assessment indicated impairment goodwill intangible assets consisting patents trademarks technology licenses amortized straightline basis useful lives ranging years sfas requires indefinitelived intangible assets tested impairment using onestep process consists comparison fair value carrying value intangible asset intangible assets deemed impaired net book value exceeds estimated fair value intangible assets evaluated impairment accordance sfas described impairment longlived assets restructuring downsize streamline operations rationalize manufacturing facilities company periodically recorded restructuring charges result company made estimates judgments regarding future plans including future termination benefits exit costs approved incurred actual results could vary estimates resulting adjustment earnings product liability accruals product liability recorded undiscounted basis probable liability incurred amount liability reasonably estimated based existing information accruals adjusted periodically assessment efforts progress additional information becomes available receivables related insurance thirdparty recoveries product liabilities recorded undiscounted basis probable recovery realized classified reduction litigation charges consolidated statement earnings contingencies normal course business company subject contingencies legal proceedings claims arising business cover wide range matters including among others product liability environmental liability tax matters accordance sfas accounting contingencies company records accruals contingencies probable liability incurred amount loss reasonably estimated discussion contingencies reference made note income taxes note legal proceedings contingencies derivative financial instruments derivative financial instruments used company principally management interest rate foreign currency exposures company hold issue derivative financial instruments speculative purposes company records derivative instruments balance sheet fair value changes derivatives fair value recognized earnings unless specific hedge criteria met derivative designated fair value hedge changes fair value derivative hedged item attributable hedged risk recognized consolidated statement earnings derivative designated cash flow hedge effective portions changes fair value derivative recorded comprehensive income loss subsequently recognized consolidated statement earnings hedged item affects earnings cash flows classified consistent underlying hedged item purchased foreign currency options entire change fair value included measurement hedge effectiveness cash flow hedges ineffective portions changes fair value cash flow hedges recognized charge credit earnings company designates assigns derivatives hedges forecasted transactions specific assets specific liabilities hedged assets liabilities sold extinguished forecasted transactions hedged longer expected occur company immediately recognizes gain loss designated hedging financial instruments consolidated statement earnings shipping handling costs company typically charge customers shipping handling costs shipping handling costs charged included marketing selling administrative expenses million million million respectively table contents bristolmyers squibb company notes consolidated financial statements continued note accounting policies continued advertising costs advertising costs expensed incurred advertising expense million million million respectively milestone payments company time time enter strategic alliances third parties give company rights develop manufacture market andor sell pharmaceutical products rights owned third parties result alliances company may obligated make payments alliance partners contingent upon achievement certain predetermined criteria milestones achieved prior marketing approval product payments expensed research development product approval additional milestones capitalized amortized cost products sold remaining useful life asset capitalized milestone payments tested recoverability whenever events changes circumstances indicate carrying amounts may recoverable acquired inprocess research development fair value inprocess research development acquired business combination determined independent appraisal based present value research projects projected cash flows income approach utilized consistent guidance practice aid assets acquired business combinations used research development activities focus software electronic devices pharmaceutical industries issued american institute certified public accountants future cash flows predominately based net income forecast project consistent historical pricing margins expense levels similar products revenues estimated based relevant market size growth factors expected industry trends individual project life cycles life research projects underlying patent determining fair value research project expected revenues first adjusted technical risk completion resulting cash flows discounted rate approximating companys weighted average cost capital acquired inprocess research development expensed incurred underlying product received regulatory approval future alternative use addition costs nonrefundable related acquisition licensing products yet received regulatory approval marketed alternative future use charged earnings incurred earnings per share basic earnings per common share computed using weightedaverage number shares outstanding year diluted earnings per common share computed using weightedaverage number shares outstanding year plus incremental shares outstanding assuming exercise dilutive stock options restricted stock convertible instruments foreign currency translation net assets companys foreign subsidiaries translated us dollars using current exchange rates us dollar effects arise translating net assets subsidiaries changing rates recorded foreign currency translation adjustment account included comprehensive income stock compensation plans currently company applies accounting principles board apb opinion accounting stock issued employees related interpretations accounting stockbased compensation plans discloses pro forma net income related pro forma income per share information accordance sfas accounting stockbased compensation sfas accounting stockbased compensation coststransition disclosure company recognize compensation expense stock options granted plans exercise price option date grant equal fair market value date grants restricted stock company recognizes compensation expense straightline basis period restrictions expire table contents bristolmyers squibb company notes consolidated financial statements continued note accounting policies continued following table summarizes companys results pro forma basis recorded compensation expense based upon fair value grant date awards plans consistent methodology prescribed sfas dollars millions except net earnings per share data reported total stockbased employee compensation expense included reported net income net related tax effects total stockbased employee compensation expense determined fair value based method awards net related tax effects pro forma basic earnings per share reported pro forma diluted earnings per share reported pro forma options related discontinued operations impact basic diluted earnings per share see note stockholders equity additional information recently issued accounting standards december fasb issued revised sfas sfas r sharebased payment standard eliminates ability account share based compensation transactions using intrinsic valuebased method accounting principles board opinion accounting stock issued employees requires instead transactions accounted using fairvaluebased method sfas r effective financial statements issued first interim period beginning june currently company discloses pro forma net income related pro forma income per share information accordance sfas accounting stockbased compensation sfas accounting stockbased compensation costs transition disclosure company evaluating impact statement could material impact results operations december fasb issued fsp application sfas accounting income taxes tax deduction qualified production activities provided american jobs creation act effect adoption fsp material companys consolidated financial statements see income taxes december fasb issued fas exchanges nonmonetary assets provisions statement effective nonmonetary asset exchanges occurring fiscal periods beginning june provisions statement applied prospectively eliminates exception fair value measurement nonmonetary exchanges similar productive assets paragraph b apb opinion accounting nonmonetary transactions replaces exception exchanges commercial substance adoption accounting pronouncement expected material effect consolidated financial statements november fasb issued sfas inventory costs amendment arb chapter standard requires abnormal amounts idle facility related expenses recognized current period charges also requires allocation fixed production overheads costs conversion based normal capacity production facilities sfas effective inventory costs incurred fiscal years beginning june company evaluating impact statement financial position results operations table contents bristolmyers squibb company notes consolidated financial statements continued note accounting policies continued june fasb issued fsp accounting disclosure requirements related medicare prescription drug improvement modernization act medicare act medicare act introduces prescription drug benefit medicare well federal subsidy sponsors retiree health care benefit plans provide benefit least actuarially equivalent medicare part fsp requires effects new law accounted sfas employers accounting postretirement benefits pensions company adopted fsp third quarter retroactive january reduction net periodic benefit cost benefits million based remeasurement accumulated postretirement benefit obligation january effect adoption fsp material companys consolidated financial statements see item financial statementsnote pension postretirement benefit plans march emerging issues task force eitf reached consensus issue participating securities twoclass method fas requires use twoclass method computing earnings per share enterprises participating securities multiple classes common stock consensus effective fiscal periods beginning march adoption eitf affect companys consolidated financial statements december fasb revised fin consolidation variable interest entities fin requires variable interest entity consolidated company company subject majority risk loss variable interest entitys activities entitled receive majority entitys residual returns fin also requires disclosures variable interest entities company required consolidate significant variable interest consolidation requirements fin revised apply immediately variable interest entities created january existing entities first fiscal year interim period ending march certain disclosure requirements apply financial statements issued january regardless variable interest entity established accounting pronouncement material effect consolidated financial statements note alliances investments sanofiaventis company agreements sanofiaventis sanofi codevelopment cocommercialization avaproavalide irbesartan angiotensin ii receptor antagonist indicated treatment hypertension plavix clopidogrel platelet inhibitor worldwide alliance operates framework two geographic territories one americas principally united states canada puerto rico latin american countries australia europe asia accordingly two territory partnerships formed manage central expenses marketing research development royalties supply finished product individual countries general country level agreements either copromote whereby partnership formed parties sell brand comarket whereby parties operate sell brands independently place agreements expire later respect plavix respect avaproavalide americas australia europe asia ii expiration patents exclusivity rights applicable territory company acts operating partner territory covering americas australia owns majority controlling interest territory sanofis ownership interest territory company consolidates country partnership results territory records sanofis share results minority interest net taxes million million million company recorded sales territory comarketing countries germany italy spain greece million million million sanofi acts operating partner territory covering europe asia owns majority financial controlling interest territory companys ownership interest territory company accounts investment partnership entities territory equity method records share results equity net income affiliates consolidated statement earnings companys share net income partnership entities taxes million million million table contents bristolmyers squibb company notes consolidated financial statements continued note alliances investments continued company sanofi formed alliance copromotion irbesartan part company contributed irbesartan distribution rights united states sanofi paid company total million company accounted transaction sale interest license deferred amortized million income expected useful life license approximately eleven years company recognized income million million million respectively unamortized portion deferred income recorded liabilities section consolidated balance sheet million million december respectively otsuka company worldwide commercialization agreement otsuka pharmaceutical co ltd otsuka codevelop copromote abilify aripiprazole treatment schizophrenia related psychotic disorders except japan china taiwan north korea south korea philippines thailand indonesia pakistan egypt company began copromoting product otsuka us puerto rico november june company received marketing approval european commission product currently copromoted otsuka united kingdom germany also copromoted france spain company records alliance revenue contractual share net sales copromotion countries excluding united kingdom records expenses related product alliance revenue recorded company net sales based upon otsukas net sales copromotion countries company recognizes alliance revenue abilify shipped risks rewards ownership transferred otsukas customers uk company records net sales related cost products sold company also exclusive right sell abilify number countries europe americas asia countries sales commence company record net sales related cost products sold terms agreement company purchases product otsuka performs finish manufacturing sale company customers agreement expires november us puerto rico countries european union company exclusive right sell abilify agreement expires tenth anniversary first commercial sale country company exclusive right sell abilify agreement expires later tenth anniversary first commercial sale country expiration applicable patent country company recorded revenue abilify million million million total milestone payments made otsuka agreement december million million expensed acquired inprocess research development remaining million capitalized intangible assets amortized cost products sold remaining life agreement us ranging eight eleven years included million capitalized payments million payment made july attainment marketing approval european union company amortized cost products sold million million million unamortized capitalized payment balance million million december respectively imclone company commercialization agreement expiring september imclone biopharmaceutical company focused developing targeted cancer treatments codevelopment copromotion erbitux united states february us food drug administration fda approved biologics license application bla erbitux use combination irinotecan treatment patients epidermal growth factor receptor egfrexpressing metastatic colorectal cancer refractory irinotecanbased chemotherapy use single agent treatment patients egfrexpressing metastatic colorectal cancer intolerant irinotecanbased chemotherapy accordance terms agreement company paid imclone million million paid march million paid march company paid million march milestone payment initial approval erbitux additional million payable upon fda approval use treating additional tumor type agreement imclone receives distribution fee based flat rate product revenues north america addition company also codevelopment copromotion rights canada japan extent product commercialized countries table contents bristolmyers squibb company notes consolidated financial statements continued note alliances investments continued respect million milestone payments company paid imclone million expensed first quarter acquired inprocess research development million recorded additional equity investment eliminate income statement effect portion milestone payment company economic claim ownership interest imclone company accounts million approval milestone paid march license acquisition amortizes payment cost products sold expected useful life license approximately fourteen years amortization expense million unamortized portion approval payment recorded intangibles net million december company accounts investment imclone equity method records share results equity net income affiliates consolidated statement earnings company recorded pretax charge million temporary decline market value imclone based decline value imclones share companys recorded investment imclone common stock december million million respectively representing approximately imclone shares outstanding respectively per share basis carrying value imclone investment closing market price imclone shares december respectively compared respectively december company determines equity share imclones net income loss eliminating imclones results milestone revenue imclone recognizes preapproval milestone payments recorded company additional equity investment share imclones results operations company recorded net income million net losses million million respectively company recorded net sales erbitux million merck april company entered collaboration agreement merck co inc merck worldwide codevelopment copromotion muraglitazar companys dual ppar peroxisome proliferator activated receptor agonist currently phase iii clinical development use treating type diabetes december company submitted new drug application nda fda regulatory approval murgalitazar terms agreement company received million upfront payment may entitled receive additional million milestone payment december subsequently received january company entitled receive million additional payments upon achievement certain regulatory milestones company merck jointly develop clinical marketing strategy muraglitazar share equally future development commercialization costs copromote product physicians global basis merck receive payments based net sales levels upfront payment million received may deferred amortized income expected remaining useful life agreement approximately sixteen years company recognized million payments income million milestone payment deferred recorded receivable december amortized income beginning january remaining useful life agreement addition company records mercks share codevelopment costs reduction research development expense mercks share copromotion costs reduction advertising product promotion expense summary financial information following summarized financial information companys equity investments imclone joint venture sanofi europe asia unaudited dollars millions revenues gross profit net income current assets noncurrent assets current liabilities noncurrent liabilities table contents bristolmyers squibb company notes consolidated financial statements continued note restructuring items activities company recorded pretax restructuring charges million relating downsizing streamlining worldwide operations rationalization worldwide manufacturing operations charge million relates primarily employee termination benefits approximately employees including manufacturing administrative sales personnel europe north america asia latin america exit costs million relate primarily lease termination costs items million relate primarily relocation expenses result consolidation research facilities charges partially offset adjustment due changes estimates prior period reserves million principally due reduced separation costs also million gain sale research facility previously written restructuring company expects complete restructuring activities following table presents detail provision restructuring items operating segment type company allocate restructuring charges business segments employee employee termination exit terminations benefits costs items total dollars millions pharmaceuticals healthcare reduction reserves changes estimates gain sale research property provision restructuring items addition company recorded million asset impairments accelerated depreciation relating rationalization manufacturing operations primarily cost products sold million research development related upfront payments licensing agreements allocated business segments activities company recorded pretax restructuring charges million relating downsizing streamlining worldwide operations rationalization worldwide manufacturing operations charge million relates primarily termination benefits approximately employees including manufacturing administrative sales personnel europe north america asia latin america items million relate primarily relocation expenses result consolidation research facilities charges partially offset adjustment due changes estimates prior period reserves million principally due higher anticipated proceeds disposal assets reduced separation costs company expects complete restructuring activities following table presents detail provision restructuring items operating segment type company allocate restructuring charges business segments employee employee termination exit terminations benefits costs items total dollars millions pharmaceuticals healthcare subtotal reduction reserves changes estimates provision restructuring items addition company recorded million asset impairments accelerated depreciation relating rationalization manufacturing operations cost products sold million research development related upfront payments four licensing agreements allocated business segments table contents bristolmyers squibb company notes consolidated financial statements continued note restructuring items continued activities company recorded pretax restructuring charges million relating reduction elimination nonstrategic research efforts well consolidation research facilities workforce reductions downsizing streamlining worldwide operations charge million relates employee termination benefits approximately employees including research manufacturing sales administrative personnel million represents asset writedowns including million impairment charge companys investment deltagen million exit costs closure facilities related expenses charges offset adjustment prior period restructuring reserves million million due lower expected separation costs million due higher anticipated proceeds disposal assets previously written restructuring million projects cancelled addition million adjustment cost products sold made reflect reversal inventory reserves associated cancelled projects company completed restructuring activities following table presents detail provision restructuring items operating segment type company allocate restructuring charges business segments employee employee termination exit terminations benefits costs items total dollars millions pharmaceuticals nutritionals healthcare corporateother subtotal reduction reserves changes estimates provisions restructuring items addition million accelerated depreciation relating planned shutdown research facilities united states included research development expense million inventory writeoffs associated projects included cost products sold third quarter company recorded pretax restructuring charge million severance exit costs associated consolidation research development efforts closure two leased facilities result action impairment assessment performed long lived assets used sites accordance sfas company concluded although million assets recoverable remaining useful life assets mainly laboratory equipment leasehold improvements alternate use residual value accelerated years months reflect date abandonment facilities fourth quarter table contents bristolmyers squibb company notes consolidated financial statements continued note restructuring items continued rollforward restructuring charges spending liabilities associated prior current actions follows employee termination exit cost liability liability total dollars millions balance december charges spending changes estimate balance december charges spending changes estimate balance december charges spending changes estimate balance december liabilities included accrued expenses consolidated balance sheet note acquisitions divestitures february company completed divestiture adult nutritional business novartis ag novartis million included million contingent achievement contractual requirements satisfied million upfront payment supply agreement company recorded pretax gain million million net tax included million contingent payment million reduction company goodwill associated mead johnson product lines adult nutritional products recorded sales million april company completed acquisition acordis speciality fibres acordis headquartered united kingdom supplies materials convatec wound therapeutics line acquisition expected strengthen companys leadership position wound therapies company purchased stock acordis million incurred million acquisition costs connection transaction additional million payment contingent achievement future sales volumes purchase price acquisition allocated tangible identifiable intangible assets acquired liabilities assumed based estimated fair values acquisition date million million allocated inprocess research development represents estimated fair value acquired inprocess projects consisting primarily medicel wound therapeutics product yet reached technological feasibility alternative future use therefore expensed estimated fair value projects determined employment discounted cash flow model million assigned identifiable intangible assets predominantly patents excess purchase price estimated fair values net assets acquired approximately million recorded goodwill acquisition accounted purchase method accordingly results operations included accompanying consolidated financial statements date acquisition company completed sale two branded products moisturel duricef resulted pretax gain million note discontinued operations december committed plan sell otn entered definitive sale agreement one equity partners llc otn leading specialty distributor pharmaceutical products officebased oncologists united states formerly reported distinct operating segment transaction expected completed first half sale price equal million plus sale price adjustment sale price adjustment based excess current assets current table contents bristolmyers squibb company notes consolidated financial statements continued note discontinued operations continued liabilities working capital closing date sale price shall increased decreased amount working capital exceeds less million closing date sale result pretax gain approximately million subject sale price adjustment postclosing matters gain sale otn recognized closing date following amounts related otn business segregated continuing operations reported discontinued operations reflect costs certain services provided otn company costs allocated company otn services include legal counsel insurance external audit fees payroll processing certain human resource services information technology systems support year ended december dollars millions net sales cost products sold gross profit total operating expenses earnings income taxes provision income taxes net earnings discontinued operations net earnings discontinued operations also includes million statement earnings primarily related reduction tax contingency reserve related spinoff zimmer holdings inc following summary assets liabilities discontinued operations expected sold amounts presented derived historical financial information otn adjusted exclude cash intercompany receivables payables otn company excluded divestiture addition goodwill related otn december million excluded following summary net assets disposed considered determining gain sale date transaction consummated dollars millions assets receivables net current assets total current assets property plant equipment noncurrent assets total assets liabilities accounts payable accrued expenses total liabilities net assets sold accounts payable balance primarily includes payables mckesson corporation mckesson december usually paid within first five days month goods shipped preceding month result timing accounts payable balances otn net liability balance december consolidated statement cash flows includes otn business periods presented company uses centralized approach cash management financing operations accordingly debt allocated business cash inflows operating investing activities discontinued operations million million years ended december respectively cash outflows million year ended december table contents bristolmyers squibb company notes consolidated financial statements continued note earnings per share numerator basic earnings per share net earnings available common stockholders numerator diluted earnings per share net earnings available common stockholders interest expense added back assumed conversion convertible debt common shares denominator basic earnings per share weighted average number common shares outstanding period denominator diluted earnings per share weighted average shares outstanding adjusted effect dilutive stock options computations basic earnings per common share diluted earnings per common share follows year ended december dollars millions except per share amounts earnings continuing operations discontinued operations net earnings net gain disposal net earnings basic average common shares outstanding earnings continuing operations discontinued operations net earnings net gain disposal net earnings diluted average common shares outstanding conversion convertible debt bonds incremental shares outstanding assuming exercise dilutive stock options earnings continuing operations discontinued operations net earnings net gain disposal net earnings weightedaverage shares issuable upon exercise stock options included diluted earnings per share calculation dilutive million million million net earnings include interest expense million million respectively added back assumed conversion convertible debt common shares table contents bristolmyers squibb company notes consolidated financial statements continued note expense net components expense net year ended december dollars millions interest expense interest income foreign exchange transaction loss net net expense net interest expense reduced net interest swap gains million million million respectively interest income relates primarily cash cash equivalents investments marketable securities income includes income thirdparty contract manufacturing royalty income gains losses disposal property plant equipment note income taxes components earnings loss continuing operations minority interest income taxes year ended december dollars millions us nonus amounts categorized based location taxing authorities provisionbenefit income taxes attributable continuing operations consisted year ended december dollars millions current us nonus deferred us nonus table contents bristolmyers squibb company notes consolidated financial statements continued note income taxes continued companys provision income taxes different amount computed applying statutory us federal income tax rate earnings continuing operations minority interest income taxes result following earnings minority interest income taxes dollars millions earnings continuing operations minority interest income taxes us statutory rate effect operations ireland puerto rico switzerland state local taxes net valuation allowance changes estimate contingent tax matters nondeductible reserves anticipated dividend repatriation ajca federal foreign valuation allowance foreign effective income tax rate earnings continuing operations minority interest income taxes compared higher effective tax rate attributable primarily million charge estimated deferred taxes taken fourth quarter anticipation repatriating approximately billion special dividends companys nonus subsidiaries pursuant ajca increase estimates contingent tax matters compared charge related establishment valuation allowance certain charitable contribution carryforwards partially offset favorable resolution certain tax refund claims increased foreign tax credits effect certain litigation reserves nondeductible increase effective tax rate effective tax rate primarily due decrease effective tax rate benefit operations ireland puerto rico switzerland treatment provisions certain litigation reserves nondeductible increase estimates contingent tax matters compared components current noncurrent deferred income tax assets liabilities december dollars millions acquired inprocess research development intercompany profit inventory items foreign tax credit carryforward deferred income alternative minimum tax research development credit carryforward charitable contribution carryforward state tax net operating loss carryforward foreign net operating loss credit carryforward postretirement pension benefits depreciation deferred foreign currency gainloss anticipated dividend repatriation ajca net valuation allowance deferred tax assets net recognized deferred income taxes current deferred income taxes noncurrent us foreign income taxes payable liabilities noncurrent total table contents bristolmyers squibb company notes consolidated financial statements continued note income taxes continued valuation allowance million december relates million foreign state net deferred tax assets million foreign state net operating loss tax credit carryforwards million charitable contribution carryforwards company currently believes likely realized income taxes paid year million million million respectively current tax benefit realized upon exercise stock options charged capital excess par value stock amounted million million million respectively december company approximately billion undistributed earnings foreign subsidiaries company accrued provision million estimated deferred taxes fourth quarter anticipation repatriating approximately billion earnings pursuant ajca companys estimate tax cost related repatriation may revised result additional guidance clarifying language may issued congress andor department treasury changes companys factual assumptions may occur taxes provided balance undistributed earnings approximately billion company invested expects invest undistributed earnings permanently offshore future earnings repatriated united states company determines earnings remitted foreseeable future additional tax provisions would required due complexities tax laws assumptions would made practicable estimate amounts income taxes would provided company settled us federal income tax returns internal revenue service irs company establishes liabilities possible assessments taxing authorities resulting known tax exposures including limited transfer pricing certain tax credits various state foreign tax matters amounts represent reasonable provision taxes ultimately expected paid may need adjusted time information becomes known december certain tax contingencies liabilities established although company reasonably estimate possible amount contingency possible contingencies could material effect changes estimates related contingent tax matters included rate reconciliation year ended december company recognized income tax benefit million due settlement certain prior year tax matters determination company expected settlement tax litigation company reorganized structure ownership many nonus subsidiaries principal purpose reorganization facilitate companys ability efficiently deploy financial resources outside united states company believes reorganization transactions generally taxfree inside outside united states possible however taxing authorities particular jurisdictions could assert tax liabilities arising reorganization transactions operations reorganized subsidiaries reasonably possible predict whether taxing authority assert tax liability reasonably estimate possible loss range loss respect asserted tax liability company would vigorously challenge assertion believes would prevail assurance result company prevail final non appealable determinations possible impact could material note receivables major categories receivables follow december dollars millions trade receivables miscellaneous receivables less allowances receivables net table contents bristolmyers squibb company notes consolidated financial statements continued note inventories major categories inventories follow december dollars millions finished goods work process raw packaging materials inventories net note consignment company experienced substantial buildup wholesaler inventories us pharmaceuticals business resulting sales incentives offered company wholesalers october company determined required restate sales earnings correct errors timing revenue recognition certain sales made two largest wholesalers us pharmaceuticals business company determined sales accounted consignment model described note accounting policiesrevenue recognition based part relationship amount nature incentives offered wholesalers amount inventory held wholesalers consignment model transactions resulted deferred revenue million december deferred revenue december inventory accounted using consignment model fully worked company recognized approximately million million million deferred revenue net sales respectively net rebates returns adjustments note property plant equipment major categories property plant equipment follow december dollars millions land buildings machinery equipment fixtures construction progress less accumulated depreciation property plant equipment net capitalized interest included categories property plant equipment shown company capitalized interest million million million years ended december respectively note goodwill changes carrying amount goodwill years ended december follows pharmaceuticals nutritionals healthcare discontinued segment segment segment operations total dollars millions balance december purchase accounting adjustments reduction due sale adult nutritional business purchase price allocation adjustments balance december table contents bristolmyers squibb company notes consolidated financial statements continued note intangible assets intangible assets major asset class follows december dollars millions patentstrademarks licenses technology less accumulated amortization net carrying amount amortization expense intangible assets majority included costs products sold years ended december million million million respectively expected amortization expense related current net carrying amount intangible assets follows years ending december dollars millions later years note shortterm borrowings longterm debt included shortterm borrowings amounts due foreign banks million million current installments longterm debt million million december respectively us shortterm borrowings primarily consist commercial paper million december average interest rate us commercial paper outstanding december proceeds commercial paper issuance used general corporate purposes average interest rates international shortterm borrowings current installments longterm debt outstanding december respectively compared respectively december december company replaced prior billion revolving credit facilities new billion five year revolving credit facility syndicate lenders extendable anniversary date consent lenders facility contains financial covenant whereby ratio consolidated debt consolidated capital exceed company compliance covenant since inception new facility borrowings outstanding revolving credit facilities december company unused shortterm lines credit foreign banks million million december respectively table contents bristolmyers squibb company notes consolidated financial statements continued note shortterm borrowings longterm debt continued components longterm debt follows december dollars millions notes due notes due floating rate convertible debentures due notes due notes due debentures due debentures due debentures due yen notes due yen notes due euro interest yen principal term loan due industrial revenue bonds due yen notes due yen notes due variable rate industrial revenue bonds due companys outstanding billion convertible debentures pay interest quarterly annual rate equal month libor reset quarterly minus yield never less zero final maturity september debentures callable par time september issuer holders also redeem debentures par september fundamental change ownership company occurs bond initial conversion price conversion rate shares adjustable depending average closing prices applicable period maximum conversion rate shares company entered fixed floating interest rate swaps billion longterm debt cash payments interest million million million respectively payments due period later total years dollars millions longterm debt obligations included shortterm borrowings companys consolidated balance sheet balances represent outstanding nominal long term debt values companys convertible debenture included due payment contains put call feature described december company provided financial guarantees form standby letters credit performance bonds majority standby letters credit insurance companies support thirdparty liability programs performance bonds relate sale company product various foreign ministries health middle east company believes significant majority guarantees expire without funded amounts obligations presented following table expiration period less total year years dollars millions standby letters credit performance bonds guarantees total commercial commitments table contents bristolmyers squibb company notes consolidated financial statements continued note stockholders equity changes common shares treasury stock capital excess par value stock restricted stock capital excess common shares treasury cost treasury par value restricted issued shares stock stock stock dollars shares millions balance december issued pursuant stock plans options amortization restricted stock lapses forfeitures restricted stock purchases balance december issued pursuant stock plans options amortization restricted stock lapses forfeitures restricted stock balance december issued pursuant stock plans options amortization restricted stock lapses forfeitures restricted stock balance december share companys preferred stock convertible shares common stock callable companys option reductions number issued shares preferred stock due conversions shares common stock dividends declared per common share accumulated balances related component comprehensive income loss follows deferred minimum accumulated foreign loss pension available currency effective liability sale comprehensive translation hedges adjustment securities incomeloss dollars millions balance december comprehensive income loss balance december comprehensive income loss balance december comprehensive income loss balance december stock compensation plans companys stock incentive plan executive officers key employees may granted options purchase companys common stock less market price date option granted options generally become exercisable installments per year first fourth anniversaries grant date maximum term years additionally plan provides granting stock appreciation rights whereby grantee may surrender exercisable rights receive common stock andor cash measured excess market price common stock option exercise price terms stock incentive plan authorized shares include outstanding shares per year well number shares tendered prior year pay purchase price options number shares previously utilized satisfy withholding tax obligations upon exercise shares available grant prior year granted year shares cancelled forfeited expired also available future grant stock incentive plan provides granting common stock key employees subject restrictions continuous employment restrictions generally expire fiveyear period date grant compensation expense table contents bristolmyers squibb company notes consolidated financial statements continued note stockholders equity continued recognized restricted period december million million shares restricted stock outstanding plan respectively million shares restricted stock granted fair value stock incentive plan also incorporates companys longterm performance awards awards delivered form target number performance shares threeyear cycle awards based eps growth sales growth ultimate payout modified companys total stockholder return versus eleven companies proxy peer group threshold targets met performance period payment made longterm performance award plan maximum performance three measures result maximum payout target december million million performance shares outstanding plan respectively million performance shares granted fair value teamshare stock option plan fulltime employees excluding key executives granted options purchase companys common stock market price date options granted company authorized million shares issuance plan individual grants generally become exercisable evenly third fourth fifth anniversary grant date maximum term years options million shares exercised plan december fair value options granted estimated per common share per common share per common share respectively date grant using blackscholes optionpricing model following assumptions dividend yield volatility riskfree interest rate expected life years stock option transactions shares common stock weighted average available issued exercise option price award plan shares shares millions balance december authorized granted exercised lapsed balance december authorized granted exercised lapsed balance december authorized granted exercised lapsed balance december table contents bristolmyers squibb company notes consolidated financial statements continued note stockholders equity continued following tables summarize information concerning companys stock compensation plans currently outstanding exercisable options number securities remaining available future issuance number equity securities weighted compensation issued average plans upon exercise excluding exercise price securities outstanding outstanding reflected options options column plan category rights rights b c shares shares millions millions equity compensation plans approved security holders equity compensation plans approved security holders options outstanding options exercisable weighted average weighted weighted remaining average average number contractual exercise number exercise range exercise prices outstanding life price exercisable price shares shares millions years millions december million shares common stock reserved issuance pursuant stock plans options conversions preferred stock options related discontinued operations included amounts material note financial instruments company exposed market risk due changes currency exchange rates interest rates accordingly company utilizes foreign exchange option forward contracts offset effect exchange rate fluctuations anticipated foreign currency transactions primarily intercompany inventory purchases expected occur within next two years company exposures net foreign currency denominated assets liabilities approximated million million december respectively primarily europe japan mexico canada foreign exchange option contracts forward contracts used hedge anticipated transactions companys primary foreign currency exposures relation us dollar euro canadian dollar australian dollar japanese yen notional amounts companys foreign exchange derivative contracts december million million respectively derivatives majority qualify hedges future anticipated cash flows effective portion changes fair value temporarily deferred comprehensive income oci recognized earnings hedged item affects earnings sfas requires company perform periodic assessments hedge effectiveness assessments determine whether derivatives designated qualifying hedges continue highly effective offsetting changes cash flows hedged items ineffective portion fair value longer deferred oci included current period earnings year ended december company recognized loss due ineffective contracts million fair value option forward contracts liabilities million million december respectively recorded assets accrued liabilities december fair value foreign exchange contracts based yearend currency rates black scholes model case option contracts addition foreign exchange hedge contracts noted company also uses foreign exchange forward contracts hedge foreign currency denominated monetary assets liabilities primary objective foreign exchange forward contracts protect us dollar value foreign currency denominated monetary assets liabilities effects table contents bristolmyers squibb company notes consolidated financial statements continued note financial instruments continued volatility foreign exchange might occur prior receipt settlement us dollars foreign currency denominated monetary assets liabilities primarily denominated japanese yen euro forward contracts designated hedges marked market incomeexpense notional fair value amount foreign exchange forward contracts december million million respectively company uses derivative instruments part interest rate risk management policy derivative instruments used comprised principally fixed floating rate interest rate swaps subject fairvalue hedge accounting treatment company entered several fixed floating interest rate swap contracts several financial institutions notional amounts swaps billion billion december respectively accordance sfas accounting derivative instruments hedging activities company recognized net reduction interest expense million million million respectively reflects benefit lower floating rate obtained swap compared fixed rate underlying debt swap contracts well underlying debt hedged recorded fair value resulted increase noncurrent assets million shortterm liabilities million longterm debt million increase noncurrent assets long term debt million december respectively swap contracts generally held maturity company use derivative financial instruments speculative purposes company reclassified deferred losses million million million respectively comprehensive income earnings majority classified cost products sold carrying amount companys financial instruments includes cash cash equivalents marketable securities accounts receivable accounts payable approximates fair value december longterm debt noted difference fair value carrying value material note segment information company organized pharmaceutical company related healthcare businesses three reportable segmentspharmaceuticals nutritionals healthcare pharmaceuticals segment comprised global pharmaceutical international excluding japan consumer medicines businesses nutritionals segment consists mead johnson primarily infant formula business healthcare segment consists convatec medical imaging consumer medicines united states japan businesses companys products sold principally wholesale retail trade nationally internationally certain products also sold drug manufacturers hospitals clinics government agencies medical profession three wholesalers accounted approximately respectively companys total net sales sales wholesalers accounted respectively companys total net sales three wholesalers accounted approximately respectively companys total net sales sales concentrated pharmaceuticals segment business segments earnings minority net sales interest income taxes yearend assets dollars millions pharmaceuticals nutritionals healthcare total segments corporateother total table contents bristolmyers squibb company notes consolidated financial statements continued note segment information continued corporateother consists principally interest income interest expense certain administrative expenses allocations business segments certain corporate programs corporateother also includes gain sales businessesproduct lines million million respectively accelerated depreciation million termination benefits exit costs million million million respectively asset writedown impairment charges million million respectively upfront milestone payments licensing agreements million million respectively litigation charges net million million million respectively acquired inprocess research development charge million also includes million asset impairment charge imclone pharmaceuticals segment includes accelerated depreciation million certain manufacturing facilities north america expected closed relocation million retention million pharmaceuticals includes litigation settlement income million upfront payment licensing agreement million million accelerated depreciation assets manufacturing facilities north america expected closed end million charge asset impairment million charge relocation expenses million charge retention bonus benefits additionally pharmaceuticals segment includes charge acquired inprocess research development million corporateother assets include cash cash equivalents marketable securities goodwill assets otn held available sale certain assets capital expenditures depreciation dollars millions pharmaceuticals nutritionals healthcare total segments corporateother total geographic areas net sales yearend assets dollars millions united states europe middle east africa western hemisphere pacific total table contents bristolmyers squibb company notes consolidated financial statements continued note leases minimum rental commitments noncancelable operating leases primarily real estate motor vehicles effect december years ending december dollars millions later years total minimum payments less total minimum sublease rentals net minimum rental commitments operating lease rental expense net sublease rental income million million million million million million note pension postretirement benefit plans company certain subsidiaries defined benefit pension plans defined contribution plans regular fulltime employees principal pension plan bristolmyers squibb retirement income plan funding policy contribute amounts provide current service fund past service liability plan benefits based primarily years credited service participants compensation plan assets consist principally equity fixed income securities company also provides comprehensive medical group life benefits substantially us retirees elect participate comprehensive medical group life plans medical plan contributory contributions adjusted periodically vary date retirement original retiring company life insurance plan noncontributory plan assets consist principally equity fixedincome securities similar plans exist employees certain countries outside united states cost companys deferred benefits postretirement benefit plans included following components pension benefits benefits dollars millions service cost benefits earned year interest cost projected benefit obligation expected return plan assets net amortization deferral net periodic benefit cost curtailments settlements total net periodic benefit cost company recognized impact medicare prescription drug improvement modernization act accordance fsp recorded million reduction net periodic benefit cost changes benefit obligations plan assets december companys defined benefit postretirement benefit plans table contents bristolmyers squibb company notes consolidated financial statements continued note pension postretirement benefit plans continued pension benefits benefits dollars millions benefit obligation beginning year service costbenefits earned year interest cost projected benefit obligation plan participants contributions curtailments settlements actuarial gainloss plan amendments benefits paid exchange rate losses benefit obligation end year fair value plan assets beginning year actual return plan assets employer contribution plan participants contributions settlements transfer inout benefits paid exchange rate gains fair value plan assets end year funded status unamortized net obligation adoption unrecognized prior service cost unrecognized net actuarial loss net amount recognized amounts recognized balance sheet consist prepaid benefit cost accrued benefit cost intangible assets accumulated comprehensive income net amount recognized several plans underfunded accrued benefit obligations exceeded accrued benefit liabilities december additional minimum liabilities established increase accrued benefit liabilities values underfunded accrued benefit obligations liabilities totaled million million december respectively us unfunded benefit equalization plan several international plans additional minimum liability offset intangible assets million million charges comprehensive income included stockholders equity million million december respectively accumulated benefit obligation defined benefit pension plans million million december respectively information pension plans accumulated benefit obligations excess plan assets december dollars millions projected benefit obligation accumulated benefit obligation fair value plan assets table contents bristolmyers squibb company notes consolidated financial statements continued note pension postretirement benefit plans continued attributable primarily unfunded us benefit equalization plan several plans international markets unfunded us benefit equalization plan provides pension benefits employees compensation irs limits funded taxadvantaged manner additional information pertaining companys pension postretirement plans pension benefits benefits dollars millions increase minimum liability including impact foreign currency fluctuations included comprehensive income weightedaverage assumptions used determine benefit obligations december pension benefits benefits discount rate rate compensation increase weightedaverage actuarial assumptions used determine net periodic benefit cost years ended december pension benefits benefits discount rate expected longterm return plan assets rate compensation increase december companys expected longterm rate return us pension plan assets target asset allocation public equity us international private equity fixed income approximated applying expected returns public equity private equity fixed income target allocation actual historical returns also relevant annualized returns periods ended december years years years us pension plan assets represented approximately total company pension plan assets december disclosed total company expected return assets us pension plans due impact international pension plans typically employ less aggressive asset allocation expected return disclosed benefits relevant assets invested manner us pension plan assets international plan assets assumed health care cost trend rates december health care cost trend rate assumed next year rate cost trend rate assumed decline ultimate trend rate year rate reaches ultimate trend rate table contents bristolmyers squibb company notes consolidated financial statements continued note pension postretirement benefit plans continued assumed health care cost trend rates effect amounts reported health care plans onepercentagepoint change assumed health care cost trend rates would following effects percentage percentage point increase point decrease effect total service interest cost effect postretirement benefit obligation companys asset allocation pension postretirement benefits december pension benefits benefits public equity securities debt securities including cash private equity total companys investment strategy emphasizes equities order achieve high expected returns long run low expense low required cash contributions us pension plans target asset allocation public equity us international private equity fixed income maintained cash flow ie cash contributions benefit payments used rebalance back targets necessary investments well diversified within three major asset categories us equity passively managed otherwise investments actively managed investment strategies international pension plans typically similar although asset allocations usually conservative bristolmyers squibb company common stock represents less plan assets december assets postretirement benefits commingled us pension plan assets therefore investment strategy identical described us pension plans contributions although minimum contributions required company plans make cash contributions us pension plans contributions made us pension plans company may make taxdeductible contributions h account retiree medical benefits equal portion pension normal cost contributions international pension plans expected million range estimated future benefit payments following benefit payments reflect expected future service appropriate expected paid benefits pension medicare benefits gross subsidy net dollars millions years table contents bristolmyers squibb company notes consolidated financial statements continued note pension postretirement benefit plans continued savings plan principal defined contribution plan bristolmyers squibb savings investment program companys contribution based employee contributions level company match companys contributions plan million million million note legal proceedings contingencies legal proceedings contingencies various lawsuits claims proceedings investigations pending company certain subsidiaries accordance sfas accounting contingencies company records accruals contingencies probable liability incurred amount loss reasonably estimated matters involve antitrust securities patent infringement employee retirement income security act amended erisa pricing sales marketing practices environmental health safety matters product liability insurance coverage significant matters described assurance increase scope matters future lawsuits claims proceedings investigations material management continues believe previously disclosed next years aggregate impact beyond current reserves legal matters affecting company reasonably likely material companys results operations cash flows may material financial condition liquidity companys decision obtain insurance coverage dependent market conditions including cost availability existing time decisions made result external factors availability insurance become restrictive cost increased significantly company evaluated risks determined cost obtaining insurance outweighs benefits coverage protection losses selfinsured product liabilities effective july company continue evaluate risks benefits determine insurance needs future plavix litigation united states companys us territory partnership alliance sanofi plaintiff three pending patent infringement lawsuits instituted us district court southern district new york entitled sanofisynthelabo sanofisynthelabo inc bristolmyers squibb sanofi pharmaceuticals holding partnership v apotex inc apotex corp cv shs sanofisynthelabo sanofisynthelabo inc bristolmyers squibb sanofi pharmaceuticals holding partnership v dr reddys laboratories ltd dr reddys laboratories inc cv shs sanofisynthelabo sanofisynthelabo inc bristolmyers squibb sanofi pharmaceuticals holding partnership vs teva pharmaceuticals usa inc teva pharmaceuticals industries ltd cv teva pharmaceuticals industries ltd since dismissed case proceedings involving plavix also instituted outside united states significant proceedings pending canada described us suits filed march may september respectively based us patent composition matter patent discloses claims among things hydrogen sulfate salt clopidogrel marketed plavix first two suits also based us patent discloses claims among things use clopidogrel prevent secondary ischemic event plaintiffs later withdrew patent two lawsuits plaintiffs infringement position based defendants filing abbreviated new drug applications anda fda seeking approval sell generic clopidogrel bisulfate prior expiration composition matter patent defendants responded alleging patent invalid andor unenforceable apotex added antitrust counterclaims first two cases consolidated discovery fact discovery closed october expert discovery completed november trial could occur early second quarter although may occur later discovery yet commenced third action companys us territory partnership alliance sanofi plaintiff another pending patent infringement lawsuit instituted us district court district new jersey entitled sanofisynthelabo sanofisynthelabo inc bristolmyers squibb sanofi pharmaceuticals holding partnership v watson pharmaceuticals inc watson laboratories inc cv suit filed october based us patent discloses claims particular crystalline polymorph form hydrogen sulfate salt clopidogrel marketed plavix case early stages discovery yet begun table contents bristolmyers squibb company notes consolidated financial statements continued note legal proceedings contingencies continued plavix currently companys largest product ranked net sales net sales plavix approximately billion billion years ended december respectively currently company expects plavix market exclusivity united states composition matter patent plavix found infringed invalid andor unenforceable district court level fda could approve defendants andas sell generic clopidogrel generic competition plavix could begin company exhausted appeals generic competition would likely result substantial decreases sales plavix united states although plaintiffs intend vigorously pursue enforcement patent rights plavix possible time reasonably assess outcome lawsuits company prevail lawsuits timing potential generic competition plavix however generic competition us occur company believes unlikely occur second half also possible reasonably estimate impact lawsuits company however loss market exclusivity plavix subsequent development generic competition would material companys sales plavix results operations cash flows could material financial condition liquidity canada sanofisynthelabo sanofisynthelabo canada inc instituted prohibition action federal court canada apotex inc apotex minister health response notice allegation apotex directed canadian patent covering clopidogrel bisulfate apotexs notice allegation noa indicated filed abbreviated new drug submission ands clopidogrel bisulfate tablets sought approval notice compliance ands expiration canadian patent expires august apotexs noa alleged patent invalid infringed hearing held february february decision expected april date statutory month stay imposed approval apotexs ands expires decision favorable apotex could result generic product market canada second quarter company believes outcome canada predictive outcome us light different procedural substantive rules two jurisdictions sanofiaventis sanofisynthelabo canada inc also instituted prohibition action federal court canada novopharm limited novopharm minister health response notice allegation novopharm directed canadian patent covering clopidogrel bisulfate novopharms notice allegation noa indicated filed abbreviated new drug submission ands clopidogrel bisulfate tablets sought approval notice compliance ands expiration canadian patent expires august novopharms noa alleged patent invalid action early stages hearing date set united kingdom december aircoat limited aircoat filed nullity petition court session glasgow scotland nullity petition aircoat seeks revocation european patent registered united kingdom european patent covers inter alia clopidogrel bisulfate active ingredient plavix aircoat specifically alleges claims european patent invalid revoked grounds lack novelty andor lack inventive step patent litigation tequin company kyorin pharmaceuticals co ltd kyorin commenced patent infringement action march teva usa teva industries united states district court southern district new york relating antibiotic gatifloxacin kyorin holds composition matter patent company sells tequin teva industries since dismissed case action relates tevas filing anda generic version gatifloxacin tablets certification composition matter patent expires december invalid table contents bristolmyers squibb company notes consolidated financial statements continued note legal proceedings contingencies continued infringed filing suit places stay approval tevas generic product june unless court decision adverse company kyorin date erbitux october complaint filed yeda research development company ltd yeda imclone aventis pharmaceuticals inc us district court southern district new york action alleges seeks three individuals associated yeda also named coinventors us patent covers therapeutic combination egfrspecific monoclonal antibody antineoplastic agents chemotherapeutic agents use treatment cancer yedas action successful yeda could position practice license others practice invention could result product competition erbitux might otherwise occur company party action unable predict outcome stage proceedings may repligen corporation repligen massachusetts institute technology mit filed lawsuit united states district court district massachusetts imclone claiming imclones manufacture sale erbitux infringes patent generally covers process protein production mammalian cells repligen mit seek damages based sales erbitux commenced february patent expired may although repligen mit seeking extension patent company party action unable predict outcome stage proceedings abilify august otsuka filed united states patent trademark office uspto request reexamination us composition matter patent covering abilify antipsychotic agent used treatment schizophrenia us patent number patent expires may extended pending supplemental protection extensions granted otsuka determined original patent application contained error description prior art reference identified wrong patent number addition otsuka taken opportunity bring citations attention uspto uspto granted request reexamination reexamination proceeding ongoing reexamination proceeding allow uspto consider patentability patent claims light corrected patent number newly cited documents uspto expected make final decision reexamination within next ten fifteen months company otsuka believe invention claimed patent patentable prior art expect uspto reconfirm reexamination however guarantee outcome patentability patent reconfirmed following reexamination may sooner expected loss market exclusivity abilify subsequent development generic competition would material company avalide ranbaxy laboratories limited ranbaxy served notice filed anda piv certification directed us patent formulation patent expires june ranbaxys piv notice asserts proposed generic formulation infringe patent ranbaxys piv notice include challenge composition matter patent currently expires september company partner sanofi currently evaluating ranbaxys piv notice avapro ranbaxy served notice filed anda piv certification directed us patent formulation patent expires june ranbaxys piv notice asserts proposed generic formulation infringe patent ranbaxys piv notice include challenge composition matter patent currently expires september company partner sanofi currently evaluating ranbaxys piv notice tequin injectable form apotex corp apotex sicor pharmaceuticals inc sicor american pharmaceutical partners inc app served notice filed abbreviated ndas piv certifications directed us patent apotex sicor also submitted piv certifications us patent patent composition matter patent expires december patent term extension applied december us patent covers specific form gatifloxacin used tequin apotex sicor allege piv notices us patent invalid apotex sicor app allege proposed generic formulations would infringe us patent company currently evaluating piv notices vanlev litigation april may june company former chairman board chief executive officer charles heimbold jr former chief scientific officer peter ringrose phd named defendants number class action lawsuits alleging violations federal securities laws regulations actions consolidated one action us district table contents bristolmyers squibb company notes consolidated financial statements continued note legal proceedings contingencies continued court district new jersey plaintiff claims defendants disseminated materially false misleading statements andor failed disclose material information concerning safety efficacy commercial viability product vanlev period november april may plaintiff submitted amended complaint adding allegations company present chairman board chief executive officer peter r dolan former chairman board chief executive officer charles heimbold jr former chief scientific officer peter ringrose phd disseminated materially false misleading statements andor failed disclose material information concerning safety efficacy commercial viability vanlev period april march number related class actions making essentially allegations also filed us district court southern district new york actions transferred us district court district new jersey company filed motion partial judgment favor based upon pleadings plaintiff opposed motion part seeking amend complaint court granted part denied part companys motion ruled plaintiff may amend complaint challenge certain alleged misstatements court certified two separate classes class relating period november april class relating period march march class certification proposed class certification without prejudice defendants rights fully contest merits plaintiffs claims plaintiff purports seek compensatory damages costs expense behalf shareholders respect class period proposed class period december company defendants made motion summary judgment plaintiffs claims final pretrial conference matter commenced december scheduled completed may trial date set january plaintiff moved leave file third amended complaint seeking combine two class periods one expanded class period october march add allegations company peter r dolan charles heimbold jr peter ringrose phd disseminated materially false misleading statements failed disclose material information concerning safety efficacy commercial viability vanlev defendants opposed plaintiffs motion court scheduled hear oral argument motion april possible time reasonably assess final outcome litigation reasonably estimate possible loss range loss respect litigation company prevail final nonappealable determinations litigation impact could material securities matters period march may company number current former officers named defendants number securities class action suits suits variously alleged violations federal securities laws regulations connection three different matters vanlev discussed sales incentives wholesaler inventory levels imclone imclones product erbitux discussed allegations concerning vanlev transferred us district court district new jersey consolidated action pending remaining actions consolidated pending us district court southern district new york plaintiffs filed consolidated class action complaint april company certain current former officers alleging class period october march consolidated class action complaint alleges violations federal securities laws connection among things companys investment relationship imclone imclones product erbitux certain accounting issues including issues related wholesaler inventory sales incentives establishment reserves accounting certain asset sales plaintiffs seek compensatory damages costs expenses march us district court granted companys motion dismiss consolidated class action complaint dismissed case prejudice plaintiffs appealed dismissal second circuit court appeals court appeals appeal pending parties reached agreement principle settle action july court appeals stayed appeal remanded action district court district court could consider settlement july district court vacated clerks judgment order consider settlement also day district court entered order preliminarily approving settlement certifying class settlement purposes pursuant terms proposed settlement claims action dismissed litigation terminated defendants receive releases company pay million fund class members november fairness hearing district court approved settlement judgment dismissing case prejudice settlement become final company discussing recovery insurance policies reflected financial statements portion million settlement approximately million shares excluded settlement pursuant requests exclusion approximately million shares held plaintiffs four pending actions discussed company established reserves liabilities possible time reasonably assess final outcome lawsuits accordance gaap company determined amounts represent minimum expected probable losses respect lawsuits eventual losses related table contents bristolmyers squibb company notes consolidated financial statements continued note legal proceedings contingencies continued lawsuits may exceed reserves impact could material company believe topend range losses estimated addition action filed early october new york state supreme court making similar factual allegations asserting variety claims including among others common law fraud negligent misrepresentation discovery taken matter january company moved dismiss complaint plaintiffs filed amended complaint december making similar allegations also adding allegations sec complaint issued august company filed motion dismiss amended complaint february plaintiffs opposition motion dismiss due march companys reply due april three related actions filed one september one november one december making similar factual allegations asserting claims similar made amended complaint new york state supreme court action filed october company intends file motion dismiss related actions briefing schedule identical action filed october possible time reasonably assess final outcome litigation reasonably estimate possible loss range loss respect litigation company prevail final nonapplicable determinations litigation impact could material company number companys current former officers named defendants purported class action filed october state court cook county illinois complaint makes factual allegations similar made settled federal class action southern district new york asserts common law fraud breach fiduciary duty claims complaint purports assert claims behalf stockholders purchased companys stock october held onto stock march company removed action northern district illinois february plaintiffs motion remand due march companys opposition due april plaintiffs reply due may possible time reasonably assess final outcome litigation reasonably estimate possible loss range loss respect litigation company prevail final nonapplicable determinations litigation impact could material november class action complaint filed united states district court eastern district missouri company k healthcare resources inc k several current former k directors officers behalf purchasers k stock august september class action complaint alleges company participated fraudulently inflating value k stock allegedly engaging improper channelstuffing agreements k bms filed motion dismiss case january plaintiffs opposition motion dismiss due march companys reply due april private securities litigation reform act discovery automatically stayed pending outcome motion dismiss plaintiff filed motion partially lift automatic discovery stay february companys opposition motion due march plaintiffs reply due march impact expected material beginning october number companys current former officers directors named defendants three shareholder derivative suits pending us district court southern district new york number companys current former officers directors named defendants three shareholder derivative suits filed period march may us district court district new jersey july us district court district new jersey ordered three shareholder derivative lawsuits filed court transferred us district court southern district new york subsequently us district court southern district new york ordered six federal shareholder derivative suits consolidated plaintiffs filed consolidated amended verified shareholder complaint certain members board directors current former officers pricewaterhousecoopers pwc independent registered public accounting firm customary derivative suits company named defendant action nominal defendant company liable damages suit specific relief sought company consolidated amended complaint alleges among things violations federal securities laws breaches fiduciary duty certain individual defendants connection companys conduct concerning among things safety efficacy commercial viability vanlev discussed companys sales incentives certain wholesalers inventory levels wholesalers companys investment relations imclone imclones product erbitux alleged anticompetitive behavior connection buspar taxol lawsuit also alleges malpractice negligent misrepresentation negligence pwc plaintiffs seek restitution rescission certain officers directors compensation alleged improper insider trading proceeds injunctive relief fees costs expenses contribution certain officers alleged liability consolidated securities class action pending us district court southern district new york discussed contribution indemnification pwc discovery taken matter december company moved dismiss consolidated amended complaint motion dismiss administratively withdrawn without prejudice party right reinstated upon request two similar actions pending new york state court plaintiffs seek equitable relief damages costs attorneys fees parties currently engaged discussions regarding potential settlement action previously disclosed august company entered final settlement sec concluding investigation concerning certain wholesaler inventory accounting matters settlement reached consent copy attached exhibit companys quarterly report form q period ended september consent company agreed without admitting denying liability violate certain provisions securities laws company also agreed establish million fund class shareholders distributed courts supervision million fund included million civil penalty distributed certain company shareholders plan distribution established sec table contents bristolmyers squibb company notes consolidated financial statements continued note legal proceedings contingencies continued settlement resolve ongoing investigation sec activities certain current former members companys management connection wholesaler inventory issues accounting matters investigation ongoing addition investigation us attorneys office district new jersey concerning inventory accounting matters covered companys settlement sec continuing company continuing cooperate investigations erisa litigation december first quarter company others named defendants five class actions brought erisa us district courts southern district new york district new jersey actions consolidated southern district new york caption bristolmyers squibb co erisa litigation cv lap amended consolidated complaint alleging class period january march served august amended consolidated complaint brought behalf four named plaintiffs putative class consisting participants bristolmyers squibb company savings investment program savings plan beneficiaries whose benefit savings plan held andor acquired company stock time class period excluding defendants heirs predecessors successors assigns named defendants company bristolmyers squibb company savings plan committee committee thirteen individuals presently serve committee served committee recent past charles heimbold jr peter r dolan past present chief executive officers respectively company amended consolidated complaint generally alleges defendants breached fiduciary duties erisa class period among things continuing offer company stock fund company stock investment alternatives savings plan continuing invest company matching contributions company stock fund company stock failing disclose investments company stock allegedly imprudent savings plans purchases company stock january alleged transactions prohibited erisa finally defendants heimbold dolan alleged breached fiduciary duties erisa failing monitor actions committee erisa claims predicated upon factual allegations similar raised securities matters concerning among things safety efficacy commercial viability vanlev companys sales incentives certain wholesalers inventory levels wholesalers companys investment relations imclone imclones product erbitux alleged anticompetitive behavior connection buspar taxol significant discovery date discovery currently stayed october company defendants moved dismiss amended consolidated complaint plaintiffs opposed motion dismiss defendants replied motions dismiss administratively withdrawn without prejudice plaintiffs requested premotion conference intend ask court leave file second amendment complaint second quarter company established reserves liabilities litigation million possible time reasonably assess final outcome litigation accordance gaap company determined reserves established represent minimum expected probable losses respect litigation eventual losses related litigation may exceed reserves impact could material company believe topend range losses estimated company prevail final nonappealable determination matter impact could material results operations pricing sales promotional practices litigation investigations company together number pharmaceutical manufacturers defendant several private class actions actions brought nevada montana pennsylvania wisconsin kentucky illinois alabama attorneys general city new york four new york counties pending federal state courts relating pricing certain company products federal cases related state court cases removed federal courts consolidated pretrial purposes caption pharmaceutical industry average wholesale price litigation mdl civ action cvpbs united states district court judge patti b saris united states district court district massachusetts awp multidistrict litigation june private plaintiffs awp multidistrict litigation filed amended master consolidated complaint amended master complaint amended master complaint contains two sets allegations company first alleges companys many pharmaceutical manufacturers reporting prices certain drug products listed drugs companys case effect falsely overstating average wholesale price awp published industry compendia turn improperly inflated reimbursement paid medical providers pharmacists others prescribed administered sold products consumers second alleges company certain defendant pharmaceutical manufacturers conspired one another program called together rx card program fix awps certain drugs made available consumers program amended master complaint asserts claims federal rico antitrust statutes state consumer protection fair trade statutes table contents bristolmyers squibb company notes consolidated financial statements continued note legal proceedings contingencies continued amended master complaint brought behalf two main proposed classes whose definitions subject amendment case progressed december proposed classes may summarized persons entities forward paid reimbursed part listed drug medicare part b private contract expressly used awp pricing standard persons entities forward paid reimbursed portion purchase price drug covered together rx card program based whole part awp first class divided several proposed subclasses depending whether listed drug question physicianadministered selfadministered sold pharmacy benefits manager specialty pharmacy brandname generic drug september plaintiffs awp multidistrict litigation moved certification proposed plaintiff class parties briefed motion related amended proposed definition first main class subclasses discussed motion heard court february company defendants moved dismiss amended master complaint grounds fails state claims applicable statutes february court denied motion large part although court dismissed one plaintiffs claims failure plead cognizable rico enterprise accordingly court required company defendants answer amended master complaint court subsequently ordered five defendants including company engage accelerated discovery respect remaining allegations amended master complaint allegations related together rx extended discovery schedule accelerated discovery closed five defendants january addition company defendants obtained discovery named plaintiffs several nonparties benefits consultants federal government health insurers current schedule calls expert reports expert depositions summary judgment briefing liability issues first half cases commenced nevada montana pennsylvania wisconsin illinois alabama kentucky attorneys general attorneys general awp cases cases commenced new york city four new york counties new york city county awp cases include fraud consumer protection claims similar amended master complaint certain states city counties also made additional allegations defendants including company violated state medicaid statutes among things failing provide states adequate rebates required federal law attorneys general awp cases montana action proceeding respective state courts series decisions june september october affecting montana attorney generals case new york city county awp cases proceeding awp multidistrict litigation coordination private class actions court declined find medicaid rebate claims preempted federal law nevertheless dismissed many claims relating rebate payments made several drug manufacturers including claims relating company insufficiently pled court allowed proceed state law claims allege company misreported awps company filed answer claims remaining montana attorney generals complaint company also joined defendants motion dismiss pennsylvania attorney generals action decision filed february pennsylvania commonwealth court granted motion dismiss ground plaintiff failed plead complaint requisite particularity court gave attorney general days replead july nevada court denied companys defendants motions dismiss complaint except state rico claim granted attorney general leave replead opinion based prior rulings awp multidistrict litigation court company defendants also made may soon make motions dismiss attorneys general awp cases company also one number defendants private class action making awpbased claims remanded awp multidistrict litigation arizona state court individual robert j swanston asserts claims arizona state law behalf alleged class persons entities arizona paid prescription drugs based awp swanston action claims generally allege defendant drug manufacturers conspired inflate awps order dated august arizona court denied defendants motions dismiss stay proceedings parties currently briefing plaintiffs motion class certification defendants papers due february court swanston action ordered discovery matter coordinated discovery awp multidistrict litigation october company added defendant putative class action previously commenced drug manufacturers federal court alabama case brought two health care providers allegedly entitled federal statute section b public health service act discounted prices prescription drugs dispensed poor providers local areas plaintiff health care providers contend alleged class providers authorized obtain discounted prices statute may fact received level discounts entitled amended complaint company manufacturers asserts claims directly federal statute well table contents bristolmyers squibb company notes consolidated financial statements continued note legal proceedings contingencies continued state law unjust enrichment accounting company joined motion dismiss complaint filed original manufacturer defendants courts approval made applicable amended complaint finally company defendant related state court proceedings commenced new york new jersey california tennessee proceedings transferred awp multidistrict litigation pretrial purposes plaintiffs california new jersey actions sought remand cases state courts california remand motions denied new jersey remand motion remains pending cases preliminary stage company unable assess outcome possible effects business profitability reasonably estimate possible loss range loss respect cases company prevail final nonappealable determinations litigations investigations impact could material company together number pharmaceutical manufacturers also received subpoenas document requests various government agencies seeking records relating pricing sales marketing practices best price reporting drugs covered medicare andor medicaid requests records come us attorneys offices district massachusetts eastern district pennsylvania northern district texas civil division department justice offices inspector general department health human services office personnel management conjunction civil division department justice several states addition requests information come house committee energy commerce senate finance committee connection investigations committees currently conducting medicaid best price issues previously disclosed mid company initiated internal review certain sales marketing practices focusing whether practices comply applicable antikickback laws analyzing practices respect compliance best price reporting rebate requirements medicaid program certain us governmental programs reference medicaid rebate program applicable fda requirements company met representatives us attorneys office district massachusetts discuss review received related subpoenas us attorneys office companys internal review expected continue resolution pending governmental investigations related matters company producing documents actively cooperating investigations could result assertion civil andor criminal claims second quarter company increased reserves liabilities relation pharmaceutical pricing sales marketing practices described section million bringing total reserves liabilities matters million possible time reasonably assess final outcome matters accordance gaap company determined amount represents minimum expected probable losses respect matters losses could include imposition fines penalties administrative remedies andor liability additional rebate amounts eventual losses related matters may exceed reserves impact could material company believe topend range losses estimated company prevail final nonappealable determinations litigations investigations impact could material previously disclosed company undertook analysis methods processes calculating prices reporting governmental rebate pricing programs related us pharmaceuticals business analysis completed early based analysis company identified need revisions methodology processes used calculating reported pricing related rebate amounts expects implement revised methodologies processes beginning reporting federal government agency primary responsibility rebate price reporting obligations centers medicare medicaid services cms first quarter addition using revised methodologies processes company also recalculated best price average manufacturers price required reported companys federal medicaid rebate agreement certain state agreements corresponding revised rebate liability amounts programs threeyear period third quarter based results companys analysis time company recorded additional liability equal estimated additional rebate liability resulting proposed revisions material upon completion analysis early company finally determined estimated rebate liability programs threeyear period actually less rebates paid company period accordingly fourth quarter company reversed additional rebate liability recorded third quarter recorded additional reduction rebate liability amount estimated overpayment companys proposed revisions updated estimate submitted review cms company anticipates submission cms also likely reviewed department justice doj conjunction previously disclosed subpoena received company doj relating among things best price reporting drugs covered medicaid discussed detail agencies may take position table contents bristolmyers squibb company notes consolidated financial statements continued note legal proceedings contingencies continued revisions companys methodologies calculations required upon completion governmental review company determine whether recalculation liability company identified programs period similar programs necessary appropriate company believes based current information recalculation likely result material rebate liability however due uncertainty surrounding recoverability companys estimated overpayment arising review process described company also recorded reserve amount equal estimated overpayment company remediated internal controls processes procedures company believes resulted proposed revisions continue strengthen internal controls company received civil investigative demand attorney general state missouri relating directtoconsumer advertising pravachol period company received written confirmation attorney general july concluding investigation action taken company company also received notice putative class action lawsuit involving issues related directtoconsumer advertising filed february circuit court jackson county missouri kansas city caption richard summers v bristolmyers squibb company company served complaint march removed action federal court action remanded state court impact expected material company together number pharmaceutical manufacturers named defendant action filed california state superior court oakland james clayworth et al v bristolmyers squibb company et al alleging defendants conspired fix prices pharmaceuticals preventing importation foreign drugs united states asserting claims californias cartwright act unfair competition law plaintiffs seek treble damages damages sustained restitution profit obtained defendants charging artificially higher prices plaintiffs injunction barring defendants charging plaintiffs higher prices offered customers award reasonable attorneys fees costs relief court deems proper plaintiffs propounded interrogatories defendants served objections responses january parties process meeting conferring resolve disputes defendants responses objections plaintiffs also propounded form interrogatories requests admission request production documents company preparing responses objections discovery requests november company filed demurrer action plaintiffs filed opposition brief december company filed reply brief january oral argument demurrer held february order dated february court sustained demurrer court also granted plaintiffs leave file second amended complaint already done defendants response second amended complaint filed march case preliminary stage company unable assess outcome possible effect business profitability reasonably estimate possible loss range loss respect case company prevail final nonappealable determination litigation impact could material product liability litigation company party product liability lawsuits involving allegations injury caused companys pharmaceutical overthecounter medications majority lawsuits involve certain overthecounter medications containing phenylpropanolamine ppa companys serzone stadol ns prescription drugs addition lawsuits company also faces unfiled claims involving products ppa may yale university published results hemorrhagic stroke project concluded evidence suggestion ppa may increase risk hemorrhagic stroke limited population november fda issued public health advisory requested manufacturers ppacontaining products voluntarily cease manufacturing marketing time ppacontaining products manufactured sold company comtrex liquigel formulations naldecon november company well manufacturers ppa containing products discontinued manufacture marketing ppacontaining products allowed customers return unused product possession january company served first ppa lawsuit company currently defendant approximately personal injury lawsuits filed behalf approximately plaintiffs federal state courts throughout united states many lawsuits involve multiple defendants among claims plaintiffs allege ppa causes hemorrhagic ischemic strokes defendants aware risk failed warn consumers failed remove ppa products plaintiffs seek compensatory punitive damages federal cases transferred us district court western district washington phenylpropanolamine ppa products liability litigation mdl district court denied motions class certification class action lawsuits pending company litigation table contents bristolmyers squibb company notes consolidated financial statements continued note legal proceedings contingencies continued june district court issued ruling effectively limiting plaintiffs claims hemorrhagic ischemic strokes rulings favorable defendants included inadmissibility expert testimony cases alleging injuries occurring three days ingestion ppacontaining product cases involving psychoses seizures cardiac injuries company expects dismissed additional cases products never used plaintiffs plaintiffs alleged injury occurred three days ingestion ppacontaining product plaintiff suffered cardiac injuries psychoses serzone serzone nefazodone hydrochloride antidepressant launched company may canada march united states december company added black box warning serzone label warning potential risk severe hepatic events including possible liver failure need transplantation risk death within several months black box warning added package insert serzone number lawsuits including several class actions filed company plaintiffs allege company knew known hepatic risks posed serzone failed adequately warn physicians users risks seek compensatory punitive damages medical monitoring refunds costs purchasing serzone may company announced following evaluation commercial potential product generic entry marketplace rapidly declining brand sales decided discontinue manufacture sale product effective june present company approximately lawsuits behalf approximately plaintiffs pending federal state courts throughout united states twentyseven cases pending new york state court consolidated pretrial discovery addition approximately alleged unfiled claims injury associated serzone august federal cases transferred us district court southern district west virginia serzone products liability litigation mdl although discovery still early stage appears cases involve liver failure june district court dismissed class claims two class action complaints purported class action also filed illinois although number class action complaints filed company sought certification one personal injury classes remaining class action complaints seek certification personal injury classes addition cases filed united states four national class actions filed canada without admitting wrongdoing liability around october company entered settlement agreement respect claims united states territories regarding serzone settlement agreement embodies schedule payments dependent upon whether class member developed qualifying medical condition whether demonstrate purchased took serzone whether certain criteria apply settlement subject final approval district court appeals therefrom pursuant settlement agreement plaintiffs class counsel filed class action complaint seeing relief settlement class november district court conditionally certified temporary settlement class preliminarily approved settlement optout period ends april fairness hearing scheduled june pursuant terms proposed settlement claims dismissed litigation terminated defendants receive releases company commits paying least million funds class members class counsel right petition court award reasonable attorneys fees expenses fees paid company reduce amount money paid class members part settlement company may terminate settlement based upon number claims submitted number purported class members opt participate settlement instead pursue individual claims second quarter company established reserves liabilities lawsuits million possible time reasonably assess final outcome lawsuits accordance gaap company determined amounts represent minimum expected probable losses respect lawsuits eventual losses related lawsuits may exceed reserves impact could material company believe topend range losses estimated stadol ns stadol ns approved fda unscheduled opioid analgesic nasal spray february company asked fda schedule stadol ns schedule iv low potential abuse drug due postmarketing reports suggestive inappropriate use product october became schedule iv drug since company received number lawsuits involving stadol late number filed suits increased due newly passed tort reform legislation became effective january plaintiffs new suits previously asserted claims company alleged injuries may company announced following evaluation commercial potential product generic entry marketplace rapidly declining brand sales decided discontinue manufacture sale product effective june company party approximately cases pending behalf total approximately plaintiffs federal state courts throughout united states plaintiffs claim company committed fraud fda wrongfully promoted table contents bristolmyers squibb company notes consolidated financial statements continued note legal proceedings contingencies continued stadol ns nonaddictive plaintiffs allege company failed adequately warn addiction dependency risk associated use stadol ns company reached agreement principle settle lawsuits involving approximately plaintiffs addition lawsuits approximately active alleged unfiled claims majority cases claims pending mississippi second quarter company recovered insurance proceeds million respect stadol ns case breast implant litigation company together subsidiary medical engineering corporation mec certain companies remains defendant number claims lawsuits alleging damages personal injuries various types resulting polyurethanecovered breast implants smoothwalled breast implants formerly manufactured mec related company vast majority claims company direct lawsuits resolved settlements trial likewise claims potential claims company registered nationwide class action settlement approved federal district court birmingham alabama revised settlement resolved revised settlement company established accruals respect breast implant product liability litigation company believes possible loss addition amounts accrued material hormone replacement therapy hrt litigation national institute health began clinical trials involving prempro estrogen progestin premarin estrogen manufactured wyeth july jama article reported among prempro subjects increased risks breast cancer heart attacks blood clots strokes prempro phase study stopped july july company served first hrt lawsuit company products involved litigation estrace estrogenonly tablet estradiol generic estrogenonly tablet delestrogen injectable estrogen ovcon oral contraceptive containing estrogen progestin products sold companies january august company maintains estrace anda company currently defendant approximately lawsuits including abovementioned products filed behalf approximately plaintiffs federal state courts throughout united states majority lawsuits involve multiple defendants company expects dismissed many cases products never used plaintiffs allege among things products cause breast cancer stroke blood clots cardiac injuries women defendants aware risks failed warn consumers federal cases transferred us district court eastern district arkansas prempro wyeth products liability litigation mdl company vigorously defending product liability lawsuits believes majority cases claims without merit possible time reasonably assess final outcome companys pending product liability lawsuits unfiled claims certainty management opinion ultimate disposition matters material adverse effect companys financial position except otherwise indicated company believes adequate selfinsurance reserves commercially available excess insurance cover potential material losses related product liability cases claims environmental proceedings following discussion describes environmental proceedings governmental authority may involve potential monetary sanctions threshold prescribed specific sec rule civil action environmental claim could result significant liabilities updates ongoing matters resolution matters disclosed recent public filings summary environmental remediation costs results internal audit performed companys facility hopewell nj indicate operations sites wastewater treatment plant related discharges always compliance new jersey water pollution control act implementing regulations terms companys discharge permits company reported findings new jersey department environmental protection njdep february entered settlement agreement njdep november paid penalty none results audit suggest adverse impact public health company taken continue take corrective actions address identified deficiencies prevent future occurrences us environmental protection agency epa investigating industrial commercial facilities throughout us use refrigeration equipment containing ozonedepleting substances ods enforcing compliance regulations governing prevention service repair leaks ods requirements recently company performed voluntary corporatewide audit table contents bristolmyers squibb company notes consolidated financial statements continued note legal proceedings contingencies continued facilities us puerto rico use odscontaining refrigeration equipment company submitted audit report epa november identifying potential violations ods requirements several facilities currently discussions epa resolve matters addition matters covered companys audit report letter epa epa previously sent companys wholly owned subsidiary mead johnson request information regarding compliance ods requirements facility evansville indiana company responded request june epa currently process reviewing information company provided epa determines evansville facility facilities violation applicable ods requirements company could subject penalties andor required convert replace refrigeration equipment use non ods approved substitutes january njdep sent company approximately five companies information request letter relating site north brunswick township nj waste materials er squibb sons squibb wholly owned subsidiary company may disposed fill material containing industrial waste heavy metals excess residential standards discovered fall expansion project north brunswick township high school well number neighboring residential properties adjacent public park areas school board township current owners site conducting jointly financing soil remediation work work plan approved njdep asked company contribute cost remediation company discussions njdep site owners potentially responsible parties regarding scope costs work required address known conditions concern recently offered negotiate school board township terms cooperative funding agreement allocation process company also actively investigating historic use site including companys possible connection date claims asserted company september njdep issued administrative enforcement directive notice new jersey spill compensation control act requiring company approximately companies perform assessment natural resource damages implement unspecified interim remedial measures restore conditions lower passaic river directive alleges company liable historically sent bulk waste former inland chemical company facility newark nj reprocessing releases hazardous substances facility migrated newark bay continue adverse impact lower passaic river watershed subsequently epa also issued notice letter comprehensive environmental response compensation liability act cercla numerous partiesbut including companyseeking cooperation study conditions substantially stretch passaic river subject njdeps directive group parties entered consent agreement epa finance portion study epa estimates study cost million roughly half financed private party group study may also lead cleanup actions directed epa army corps engineers company working cooperatively group parties received njdep directive andor epa notice explore potential resolutions directive address risk collateral claims although company believe caused contributed contamination lower passaic river watershed company informed njdep willing discuss allegations company directive recent communications cooperating group njdep stated responsible parties cooperate njdep may perform damage assessment restoration take civil action recover remedial costs treble damages administrative costs penalties late group federal agencies designated trustees natural resources affected contamination passaic river watershed approached cooperating group solicit interest funding cooperative study possible natural resources damages nrd area study presumably would dovetail ongoing epa study ideally would joined njdep coordinate actions njdep may seek directive discussions federal trustees ongoing extent liability company may face either directive epas notice letter respect future nrd actions claims federal trustees contribution responsible parties yet determined october michigan department environmental quality mdeq sent company letter violation lov alleging unspecified period time emissions certain digestion tanks mead johnsons zeeland michigan facility exceeded applicable limit facilitys renewable operating air permit lov requires company take corrective action submit compliance program report although mdeq demanded fines penalties enforcement action could result penalties injunctive relief company contesting allegations lov company mdeq also working revisions companys air use permit although predict ultimate outcome certainty permit revisions may resolve matter without additional enforcement action need continue contesting lov december company njdep entered administrative consent order aco concerning alleged violations new jersey air pollution control act implementing regulations companys new brunswick facility pursuant aco company agreed submit permit application creating facilitywide emissions cap pay administrative fine approximately obligations satisfied early subsequently february aco amended provide company would install new cogeneration turbine new brunswick facility december would obtain air permits including required cogeneration turbine december estimated cost new cogeneration turbine approximately million company one several defendants class action suit filed superior court puerto rico february residents three wards municipality barceloneta alleging air emissions government owned operated table contents bristolmyers squibb company notes consolidated financial statements continued note legal proceedings contingencies continued wastewater treatment facility said municipality caused respiratory ailments violated local air rules company believes wastewater discharges treatment facility material compliance terms companys permit company believes litigation resolved immaterial amount however although suit five years old still initial stage even issue class certification still pending event adverse judgment companys ultimate financial liability could greater anticipated company also responsible various state federal foreign laws including cercla certain costs investigating remediating contamination resulting past industrial activity companys current former sites waste disposal reprocessing facilities operated third parties company typically estimates costs based information obtained epa counterpart state agency andor studies prepared independent consultants including total estimated costs site expected costsharing potentially responsible parties prp company accrues liabilities probable reasonably estimable december company estimated share total future costs sites approximately million million respectively recorded liabilities represents sum best estimates simple estimate reasonably made estimates minimal probable amount among range costs without taking account potential recoveries parties currently expected company paid less million excluding legal fees last five years investigation remediation matters including liabilities cercla onsite remedial obligations although possible predict certainty outcome environmental proceedings ultimate costs remediation company believe reasonably possible expenditures company may incur excess existing reserves material adverse effect business financial position results operations matters october sec notified company conducting informal inquiry activities certain companys german pharmaceutical subsidiaries employees andor agents company believes secs informal inquiry may encompass matters currently investigation staatsanwaltin prosecutor munich german although uncertain time company believes inquiry investigation may concern potential violations foreign corrupt practices act andor german law company cooperating sec german authorities possible time reasonably assess final outcome matters reasonably estimate possible loss range loss company conducting internal review pharmaceutical operations mexico total sales million twelve months ended december broad review includes areas compliance legal financial regulatory requirements companys standards business conduct ethics reviews ongoing time company unable assess impact results investigations may company indemnification officers directors companys corporate bylaws require extent permitted law company shall indemnify officers directors judgments fines penalties amounts paid settlement including legal fees appeals incurred connection civil criminal actions proceedings relates services company subsidiaries bylaws provide limit amount indemnification indemnification permitted case willful misconduct knowing violation criminal law improper personal benefit permitted laws state delaware company many years purchased directors officers insurance coverage cover claims made directors officers amounts types coverage varied period period dictated market conditions various excess policies provide additional coverage litigation matters regulatory actions described involve certain companys current former directors officers covered aforementioned indemnity applicable certain prior period insurance policies however certain indemnification payments may covered companys directors officers insurance coverage company predict certainty extent company recover insurers indemnification payments made connection litigation matters regulatory actions described july one companys insurers federal insurance company federal filed lawsuit new york supreme court company several current former officers members board directors seeking rescission alternative declarations allowing federal avoid payment certain directors officers insurance policies certain fiduciary liability insurance policies respect potential liability arising connection matters described vanlev litigation securities matters erisa litigation sections discovery taken matter parties currently engaged discussions regarding potential settlement action october another companys insurers sr international business insurance co ltd sri informed table contents bristolmyers squibb company notes consolidated financial statements continued note legal proceedings contingencies continued company intended try avoid certain insurance policies issued company grounds alleged material misrepresentation nondisclosure initiated arbitration proceedings london england sri indicated intends rely upon allegations similar described securities matters section support avoidance action note subsequent events january company announced plans divest us canadian consumer medicines business year ended december sales consumer medicines brands us canada totaled approximately million companys consumer medicines businesses japan asia pacific latin america europe middle east africa included planned divestiture november company medarex inc medarex entered worldwide collaboration develop commercialize mdx fully human antibody investigational product targeting ctla receptor mdx developed medarex currently phase iii clinical development treatment metastatic melanoma collaboration agreement became effective january time company made cash payment million medarex expensed research development additional million equity investment medarex note selected quarterly financial data unaudited first second third fourth quarter quarter quarter quarter year dollars million except per share data net sales gross margin earnings continuing operations discontinued operations net net earnings earnings per common share basic earnings continuing operations discontinued operations net net earnings diluted earnings continuing operations discontinued operations net net earnings dividends declared per common share cash cash equivalents marketable securities net sales gross margin earnings continuing operations discontinued operations net net earnings table contents bristolmyers squibb company notes consolidated financial statements continued earnings per common share basic earnings continuing operations discontinued operations net net earnings diluted earnings continuing operations discontinued operations net net earnings dividends declared per common share cash cash equivalents marketable securities note earnings per share quarters may add amounts year period computed discrete basis includes litigation charges million million million second third fourth quarters respectively second quarter includes litigation settlement income million first second third fourth quarters include gain sale mead johnson adult nutritional business million million million million respectively first second third fourth quarters include provisions restructuring items million million million million respectively first second third fourth quarters include upfront payments licensing agreements million million million million respectively second third quarters include writeoffs acquired process research development million million respectively includes litigation settlement charges million million second fourth quarters respectively first second third quarters include litigation settlement income million million million respectively first second third fourth quarters include provisions restructuring items million million million million respectively second third fourth quarters include reversals prior period restructuring items million million million respectively third fourth quarters include upfront payments licensing agreements million million respectively common equivalent shares excluded computation diluted earnings per share effect would antidilutive follows millions first second third fourth quarter quarter quarter quarter year table contents report independent registered public accounting firm board directors stockholders bristolmyers squibb company completed integrated audit bristolmyers squibb companys company consolidated financial statements internal control financial reporting december audits consolidated financial statements accordance standards public company accounting oversight board united states opinions based audits presented consolidated financial statements financial statement schedule opinion consolidated financial statements listed accompanying index present fairly material respects financial position company subsidiaries december results operations cash flows three years period ended december conformity accounting principles generally accepted united states america addition opinion financial statement schedule listed accompanying index presents fairly material respects information set forth therein read conjunction related consolidated financial statements financial statements financial statement schedule responsibility companys management responsibility express opinion financial statements financial statement schedule based audits conducted audits statements accordance standards public company accounting oversight board united states standards require plan perform audit obtain reasonable assurance whether financial statements free material misstatement audit financial statements includes examining test basis evidence supporting amounts disclosures financial statements assessing accounting principles used significant estimates made management evaluating overall financial statement presentation believe audits provide reasonable basis opinion internal control financial reporting also opinion managements assessment included managements report internal control financial reporting appearing item company maintained effective internal control financial reporting december based criteria established internal control integrated framework issued committee sponsoring organizations treadway commission coso fairly stated material respects based criteria furthermore opinion company maintained material respects effective internal control financial reporting december based criteria established internal control integrated framework issued coso companys management responsible maintaining effective internal control financial reporting assessment effectiveness internal control financial reporting responsibility express opinions managements assessment effectiveness companys internal control financial reporting based audit conducted audit internal control financial reporting accordance standards public company accounting oversight board united states standards require plan perform audit obtain reasonable assurance whether effective internal control financial reporting maintained material respects audit internal control financial reporting includes obtaining understanding internal control financial reporting evaluating managements assessment testing evaluating design operating effectiveness internal control performing procedures consider necessary circumstances believe audit provides reasonable basis opinions companys internal control financial reporting process designed provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles companys internal control financial reporting includes policies procedures pertain maintenance records reasonable detail accurately fairly reflect transactions dispositions assets company ii provide reasonable assurance transactions recorded necessary permit preparation financial statements accordance generally accepted accounting principles receipts expenditures company made accordance authorizations management directors company iii provide reasonable assurance regarding prevention timely detection unauthorized acquisition use disposition companys assets could material effect financial statements inherent limitations internal control financial reporting may prevent detect misstatements also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate pricewaterhousecoopers llp pricewaterhousecoopers llp philadelphia pa march table contents item changes disagreements accountants accounting financial disclosure none item controls procedures evaluation disclosure controls procedures december management carried evaluation supervision participation chief executive officer chief financial officer effectiveness design operation disclosure controls procedures term defined exchange act rule e based evaluation management concluded december disclosure controls procedures effective provide reasonable assurance company records processes summarizes reports information company must disclose reports company files submits securities exchange act amended within time periods specified secs rules forms managements report internal control financial reporting management responsible establishing maintaining adequate internal control financial reporting supervision participation management including chief executive officer chief financial officer management assessed effectiveness internal control financial reporting december based framework internal controlintegrated framework issued committee sponsoring organizations treadway commission based assessment management concluded companys internal control financial reporting effective december provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance united states generally accepted accounting principles due inherent limitations internal control financial reporting may prevent detect misstatements also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate pricewaterhousecoopers llp pwc independent registered public accounting firm audited companys financial statements included report issued report managements assessment effectiveness companys internal control financial reporting december included herein status previously disclosed internal control items making evaluation effectiveness design operation disclosure controls procedures management considered significant resources devoted substantial actions taken company past two years remediate reportable condition defined standards established american institute certified public accountants relating internal control financial reporting income taxes initially identified communicated company audit committee pwc connection audit companys consolidated financial statements year ended december repeated year ended december reportable condition identified pwc need enhance income tax accounting function provide timely analysis reconciliation income tax provision related income tax assets liabilities actions taken company included engaging outside consultant assist companys personnel conduct comprehensive detailed review certain companys income tax reporting accounting throughout company continued strengthen internal control financial reporting income taxes efforts included continuing work outside consultants making significant personnel changes including hiring new vice president taxes increasing number tax department key personnel well implementing policies procedures enhance communication business unit tax department financial reporting personnel ensure comprehensive appropriate timely review matters implementing new updating existing tax accounting policies providing training policies based evaluation chief executive officer chief financial officer concluded december internal control financial reporting income taxes issues sufficiently remediated discussed item financial statementsnote legal proceedings contingencies management identified need remediate deficiencies internal control methodology processes calculate prices reporting governmental rebate pricing programs related us pharmaceuticals business conducting evaluation chief executive officer chief financial officer also considered substantial efforts undertaken company remediate internal control deficiencies included retaining several outside consultants subject matter expertise conducting exhaustive review existing methodologies processes training employees implementation revised methodologies processes based review chief executive officer chief financial officer concluded companys internal control methodology processes calculate prices described sufficiently remediated table contents changes internal control financial reporting changes companys internal control financial reporting quarter ended december materially affected reasonably likely materially affect companys internal control financial reporting table contents part iii item directors executive officers registrant reference made proxy statement filed march respect directors registrant incorporated herein reference made part hereof response information required item b information required item respect executive officers registrant included part ia reliance general instruction g instruction item b regulation sk item executive compensation reference made proxy statement filed march respect executive compensation incorporated herein reference made part hereof response information required item item security ownership certain beneficial owners management reference made proxy statement filed march respect security ownership certain beneficial owners management incorporated herein reference made part hereof response information required item item certain relationships related transactions reference made proxy statement filed march respect certain relationships related transactions incorporated herein reference made part hereof response information required item item auditor fees reference made proxy statement filed march respect auditor fees incorporated herein reference made part hereof response information required item table contents part iv item exhibits financial statement schedules number consolidated financial statements notes consolidated financial statements report independent registered public accounting firm financial statement schedule valuation qualifying accounts schedules included additional financial data omitted applicable required information included financial statements notes thereto exhibit list exhibits listed identified numbers corresponding exhibit table item regulation sk exhibits designated two asterisks management contracts compensatory plans arrangements required filed pursuant item unless otherwise indicated exhibits part commission file number restated certificate incorporation bristolmyers squibb company incorporated herein reference exhibit c form q quarterly period ended september b bylaws bristolmyers squibb company amended january filed herewith letter agreement dated march incorporated herein reference exhibit fiscal year ended december b indenture dated june bristolmyers squibb company jpmorgan chase bank successor trustee chase manhattan bank national association incorporated herein reference exhibit form k dated may filed june c form debenture due bristolmyers squibb company incorporated herein reference exhibit form k dated may filed june form debenture due bristolmyers squibb company incorporated herein reference exhibit e fiscal year ended december e form debenture due bristolmyers squibb company incorporated herein reference exhibit f form q quarterly period ended september f five year competitive advance revolving credit facility agreement dated december among bristolmyers squibb company borrowing subsidiaries lenders named agreement bank america na syndication agent jpmorgan chase bank citicorp north america inc administrative agents filed herewith g second supplemental indenture dated september bristolmyers squibb company jpmorgan chase bank successor trustee chase manhattan bank indenture dated june previously filed exhibit annual report h form note due form note due bristolmyers squibb company incorporated herein reference exhibit g fiscal year ended december third supplemental indenture dated august bristolmyers squibb company jpmorgan chase bank trustee indenture dated june incorporated herein reference exhibit k form q quarterly period ended september j purchase agreement dated august bristolmyers squibb company goldman sachs co jp morgan securities inc representatives several purchasers named schedule agreement senior notes due senior notes due incorporated herein reference exhibit l form q quarterly period ended september table contents k exchange registration rights agreement dated august bristolmyers squibb company goldman sachs co jp morgan securities inc representatives several purchasers named schedule purchase agreement senior notes due senior notes due incorporated herein reference exhibit form q quarterly period ended september l form senior note due incorporated herein reference exhibit j form q quarterly period ended september incorporated herein reference exhibit n form q quarterly period ended september form senior note due incorporated herein reference exhibit form q quarterly period ended september n indenture dated october bristolmyers squibb company issuer jpmorgan chase bank trustee incorporated herein reference exhibit q form q quarterly period ended september registration rights agreement dated october bristolmyers squibb company goldman sachs co jp morgan securities inc representatives several purchasers named schedule purchase agreement floating rate convertible senior debentures due incorporated herein reference exhibit r form q quarterly period ended september p form floating rate convertible senior debenture due incorporated herein reference exhibit form q quarterly period ended september q purchase agreement dated september bristolmyers squibb company goldman sachs co jp morgan securities inc representatives several purchasers named schedule purchase agreement floating rate convertible debentures due incorporated herein reference exhibit form q quarterly period ended september r specimen certificate common stock incorporated herein reference exhibit fiscal year ended december specimen certificate convertible preferred stock incorporated herein reference exhibit fiscal year ended december bristolmyers squibb company stock incentive plan effective may amended effective july incorporated herein reference exhibit form q quarterly period ended june b bristolmyers squibb company stock incentive plan effective may amended effective july incorporated herein reference exhibit b form q quarterly period ended june c bristolmyers squibb company teamshare stock option plan amended restated effective september incorporated herein reference exhibit c fiscal year ended december bristolmyers squibb company executive performance incentive plan effective january incorporated herein reference exhibit b fiscal year ended december e bristolmyers squibb company executive performance incentive plan effective january incorporated herein reference exhibit proxy statement dated april f bristolmyers squibb company stock option plan amended restated october filed herewith g bristolmyers squibb company performance incentive plan amended adopted incorporated herein reference exhibit fiscal year ended december amended january incorporated herein reference exhibit b fiscal year ended december amended april incorporated herein reference exhibit b fiscal year ended december amended effective january incorporated herein reference exhibit fiscal year ended december amended effective january incorporated herein reference exhibit fiscal year ended december table contents h benefit equalization plan bristolmyers squibb company subsidiary affiliated corporations participating bristolmyers squibb company retirement income plan bristolmyers squibb puerto rico inc retirement income plan amended amended restated january amended effective october incorporated herein reference exhibit e fiscal year ended december amended effective february incorporated herein reference exhibit e fiscal year ended december benefit equalization plan bristolmyers squibb company subsidiary affiliated corporations participating bristolmyers squibb company savings investment program amended restated effective january incorporated herein reference exhibit h fiscal year ended december j squibb corporation supplementary pension plan amended previously amended restated incorporated herein reference exhibit g fiscal year ended december amended september incorporated herein reference exhibit g fiscal year ended december k bristolmyers squibb company retirement income plan nonemployee directors amended march incorporated herein reference exhibit k fiscal year ended december l bristolmyers squibb company deferred compensation plan nonemployee directors amended january filed herewith bristolmyers squibb company nonemployee directors stock option plan amended approved stockholders may incorporated herein reference exhibit registration statement form amended may incorporated herein reference exhibit c fiscal year ended december amended january incorporated herein reference exhibit fiscal year ended december n bristolmyers squibb company nonemployee directors stock option plan amended approved stockholders may incorporated herein reference exhibit proxy statement dated march squibb corporation deferral plan fees outside directors amended adopted incorporated herein reference exhibit e squibb corporation fiscal year ended december file amended effective december incorporated herein reference exhibit fiscal year ended december p amendment companys plans agreements legal documents writings pursuant action board directors october reflect change companys name bristolmyers squibb company incorporated herein reference exhibit v form k fiscal year ended december q form agreement entered bristolmyers squibb company named executive officers certain executives effective january filed herewith statement computation ratios filed herewith subsidiaries registrant filed herewith consent pricewaterhousecoopers llp filed herewith section certification letter filed herewith b section certification letter filed herewith section certification letter filed herewith b section certification letter filed herewith indicates brand names products registered trademarks owned company subsidiaries erbitux trademark imclone avapro aprovel avalide plavix trademarks sanofisynthelabo sa glucophage glucovance trademarks merck sante sas associate merck kgaa darmstadt germany abilify trademark otsuka pharmaceuticals ltd moisturel duricef trademarks galen chemicals limited javlor trademark pierre fabre medicament sa truvada trademark gilead sciences inc emsam trademark somerset pharmaceuticals inc table contents signatures pursuant requirements section securities exchange act registrant duly caused report signed behalf undersigned thereunto duly authorized bristolmyers squibb company registrant peter r dolan peter r dolan chairman board directors chief executive officer date march pursuant requirements securities exchange act report signed following persons behalf registrant capacities dates indicated signature title date peter r dolan chairman board directors chief executive march officer principal executive officer peter r dolan andrew rj bonfield senior vice president chief financial officer principal march financial officer andrew rj bonfield david l zabor vice president controller principal accounting officer march david l zabor robert e allen director march robert e allen lewis b campbell director march lewis b campbell vance coffman director march vance coffman james cornelius director march james cornelius ellen v futter director march ellen v futter louis v gerstner jr director march louis v gerstner jr laurie h glimcher md director march laurie h glimcher md leif johansson director march leif johansson james robinson iii director march james robinson iii louis w sullivan md director march louis w sullivan md table contents exhibit index